APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 2
FEBRUARY 2018



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

Cumulative Supplement 2
February 2018

CONTENTS

PAGE

1.0 INTRODUCTION v
1.1 How to use the Cumulative Supplement v
1.2 Cumulative Supplement Content vi
1.3 Applicant Name Changes vii
1.4 Levothyroxine Sodium vii
1.5 Availability of the Edition viii
1.6 Report of Counts for the Prescription Drug Product List ix
1.7 Cumulative Supplement Legend x

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act
Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Product Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability
Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

CUMULATIVE SUPPLEMENT 2
February 2018

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SAGENT AGILA LLIC (SAGENT AGILA)	MYLAN ASI LLC (MYLAN ASI)
SAGENT AGILA LLC (SAGENT AGILA LLC)	MYLAN ASI LLC (MYLAN ASI)
SAGENT STRIDES LLC (SAGENT STRIDESC)	MYLAN ASI LLC (MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference

listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharmas NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange

Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2017	MAR 2018	JUN 2018	SEP 2018	DEC 2018
DRUG PRODUCTS	19294				
LISTED SINGLE SOURCE	2758 (14.3%)				
MULTISOURCE	16536 (85.7%)				
THERAPEUTICALLY EQUIVALENT	16431 (85.2%)				
NOT THERAPEUTICALLY EQUIVALENT	105 (0.5%)				
EXCEPTIONS[1]	73 (0.4%)				
NEW MOLECULAR ENTITIES APPROVED	25				
NUMBER OF APPLICANTS	1075				

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:
The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

>A>	AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/ML	A077950	001	Mar 14, 2018	Feb	NEWA

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

>D>	+!	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Feb	CHRS
>A>	+		250MG	N202379	001	Apr 28, 2011	Feb	CHRS
>D>	+		500MG	N202379	002	Apr 14, 2017	Feb	CHRS
>A>	+!		500MG	N202379	002	Apr 14, 2017	Feb	CHRS

>A> ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

>A> TABLET;ORAL

>A> APADAZ

>A>	+	KEMPHARM	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Feb	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992	Jan	CAHN
	@		300MG;60MG	A081249	001	Jul 16, 1992	Jan	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

	@	SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Jan	DISC

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

	@	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	Jan	DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

	AA	ABHAI LLC	325MG;2.5MG	A210644	001	Feb 09, 2018	Jan	NEWA
	AA		325MG;5MG	A210644	002	Feb 09, 2018	Jan	NEWA
	AA		325MG;7.5MG	A210644	003	Feb 09, 2018	Jan	NEWA
	AA		325MG;10MG	A210644	004	Feb 09, 2018	Jan	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

>A>	AT	RISING PHARMS INC	2%	A207280	001	Mar 09, 2018	Feb	NEWA

ACYCLOVIR

TABLET;ORAL

ACYCLOVIR

>A>	AB	YILING PHARM LTD	400MG	A210401	001	Mar 07, 2018	Feb	NEWA
>A>	AB		800MG	A210401	002	Mar 07, 2018	Feb	NEWA

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

	AB	PERRIGO ISRAEL	0.1%;2.5%	A205033	001	Jan 23, 2018	Jan	NEWA
	AB	TARO	0.1%;2.5%	A206959	001	Jan 24, 2018	Jan	NEWA

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

>A>	AP	GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb	NEWA

ALBUTEROL SULFATE

TABLET;ORAL

ALBUTEROL SULFATE

	@	YAOPHARMA CO LTD	EQ 2MG BASE	A072151	001	Dec 05, 1989	Jan	CAHN
	@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Jan	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

		@	FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Jan CAHN

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

	AB		HANGZHOU BINJIANG	EQ 5MG BASE	A090258	001	Sep 24, 2009	Jan CAHN
	AB			EQ 10MG BASE	A090258	002	Sep 24, 2009	Jan CAHN
	AB			EQ 35MG BASE	A090258	003	Sep 24, 2009	Jan CAHN
	AB			EQ 70MG BASE	A090258	004	Sep 24, 2009	Jan CAHN

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

		@	FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985	Jan CAHN

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

>A>	AB		PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Feb NEWA
>A>	AB			EQ 1MG BASE	A206113	002	Feb 23, 2018	Feb NEWA

AMANTADINE HYDROCHLORIDE

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

	AB		JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	Jan NEWA
>A>		TABLET, EXTENDED RELEASE;ORAL						
>A>		OSMOLEX ER						
>A>		+	OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018	Feb NEWA
>A>		+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Feb NEWA
>A>		+!		EQ 258MG BASE	N209410	003	Feb 16, 2018	Feb NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@	YAOPHARMA CO LTD	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991	Jan CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	AB		SUN PHARM INDS INC	10MG	A089399	002	Jul 14, 1987	Jan CMFD
	AB			25MG	A089399	001	Jul 14, 1987	Jan CMFD
	AB			50MG	A089399	003	Jul 14, 1987	Jan CMFD
	AB			75MG	A089399	004	Jul 14, 1987	Jan CMFD
	AB			100MG	A089399	005	Jul 14, 1987	Jan CMFD
	AB			150MG	A089399	006	Jul 14, 1987	Jan CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

		@	FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987	Jan CAHN
		@		10MG;4MG	A071862	001	Dec 21, 1987	Jan CAHN
		@		25MG;4MG	A071064	001	Nov 27, 1987	Jan CAHN
		@		50MG;4MG	A071863	001	Dec 21, 1987	Jan CAHN
		@	SANDOZ INC	25MG;2MG	A071063	001	Nov 27, 1987	Jan CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

		@	YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
		@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
		@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>D>	AP		IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Feb CAHN
>A>	AP		SOFIE	18.8mCi-188mCi/5ML (3.75-37.5	A204667	001	Apr 22, 2015	Feb CAHN

		INJECTABLE;INTRAVENOUS						
		AMMONIA N 13						
			mCi/ML)					
		AMMONIUM LACTATE						
		CREAM;TOPICAL						
		LAC-HYDRIN						
>D>		@ RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996	Feb	CAHN
>A>		@ SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Feb	CAHN
		LOTION;TOPICAL						
		LAC-HYDRIN						
>D>		+ @ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Feb	CAHN
>A>		+ @ SUN PHARM INDS INC	EQ 12% BASE	N019155	001	Apr 24, 1985	Feb	CAHN
		ANASTROZOLE						
		TABLET;ORAL						
		ARIMIDEX						
	AB	+! ANI PHARMS INC	1MG	N020541	001	Dec 27, 1995	Jan	CAHN
		ANGIOTENSIN II ACETATE						
		SOLUTION;IV (INFUSION)						
		GIAPREZA						
		+! LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jan	CAIN
		+!	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jan	CAIN
>A>		APALUTAMIDE						
>A>		TABLET;ORAL						
>A>		ERLEADA						
>A>		+! JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb	NEWA
		APREPITANT						
		CAPSULE;ORAL						
		APREPITANT						
	AB	GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan	CAHN
	AB		80MG	A207777	002	Oct 12, 2017	Jan	CAHN
	AB		125MG	A207777	003	Oct 12, 2017	Jan	CAHN
		ARGATROBAN						
		INJECTABLE;INJECTION						
		ARGATROBAN						
	AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan	NEWA
		ARMODAFINIL						
		TABLET;ORAL						
		ARMODAFINIL						
>A>	AB	AUROBINDO PHARMA LTD	50MG	A206069	001	Mar 06, 2018	Feb	NEWA
>A>	AB		150MG	A206069	002	Mar 06, 2018	Feb	NEWA
>A>	AB		250MG	A206069	003	Mar 06, 2018	Feb	NEWA
		ASPIRIN; BUTALBITAL; CAFFEINE						
		TABLET;ORAL						
		BUTALBITAL, ASPIRIN AND CAFFEINE						
		@ FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984	Jan	CAHN
		ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE						
		TABLET;ORAL						
		ORPHENGESIC						
>A>		@ GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998	Feb	CAHN
>D>		@ PRINSTON INC	385MG;30MG;25MG	A075141	001	May 29, 1998	Feb	CAHN
		ORPHENGESIC FORTE						
>A>		@ GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	Feb	CAHN
>D>		@ PRINSTON INC	770MG;60MG;50MG	A075141	002	May 29, 1998	Feb	CAHN
		ASPIRIN; CARISOPRODOL						
		TABLET;ORAL						
		CARISOPRODOL AND ASPIRIN						
		@ OXFORD PHARMS	325MG;200MG	A040252	001	Dec 10, 1997	Jan	DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>A>	AB	DR REDDYS LABS LTD	10MG	A	090609	001	Feb 23, 2018	Feb NEWA
>A>	AB		18MG	A	090609	002	Feb 23, 2018	Feb NEWA
>A>	AB		25MG	A	090609	003	Feb 23, 2018	Feb NEWA
>A>	AB		40MG	A	090609	004	Feb 23, 2018	Feb NEWA
>A>	AB		60MG	A	090609	005	Feb 23, 2018	Feb NEWA
>A>	AB		80MG	A	090609	006	Feb 23, 2018	Feb NEWA
>A>	AB		100MG	A	090609	007	Feb 23, 2018	Feb NEWA

ATROPINE SULFATE

SOLUTION;IV (INFUSTION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

	+!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N	209260	001	Jan 26, 2018	Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

>A>		ALCON LABS INC	1%	N	208151	001	Dec 01, 2016	Feb CAHN
>D>		NOVARTIS PHARMS CORP	1%	N	208151	001	Dec 01, 2016	Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	FOSUN PHARMA	0.025MG;2.5MG	A	086173	001		Jan CAHN

LONOX

	@	FOSUN PHARMA	0.025MG;2.5MG	A	085311	002		Jan CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

	+!	ALLERGAN SALES LLC	EQ 0.5GM BASE;2GM/VIAL	N	206494	001	Feb 25, 2015	Jan CAHN

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

	@	MYLAN ASI	50,000 UNITS/VIAL	A	090211	001	May 11, 2010	Jan DISC

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

>A>		MYLAN LABS LTD	1MG/ML	A	209594	001	Mar 06, 2018	Feb NEWA

GABLOFEN

>D>	+!	PIRAMAL CRITICAL	1MG/ML	N	022462	004	Jun 22, 2012	Feb CFTG
>A> AP	+!		1MG/ML	N	022462	004	Jun 22, 2012	Feb CFTG

BARIUM SULFATE

SUSPENSION;ORAL

VARIBAR THIN HONEY

	+!	BRACCO	40% (100GM/250ML)	N	208143	006	Jan 23, 2018	Jan NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR REDIHALER

	+!	NORTON WATERFORD	0.04MG/INH	N	207921	001	Aug 03, 2017	Jan CHRS

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

	@	CHARTWELL RX	1MG	A	081264	001	Jan 23, 1992	Jan CAHN
	@		2MG	A	081265	001	Jan 23, 1992	Jan CAHN

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		HI-TECH PHARMACAL	EQ 0.05% BASE	A	209896	001	Feb 06, 2018	Jan NEWA

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		TELIGENT PHARMA INC	EQ 0.05% BASE	A	206389	001	Feb 13, 2018	Jan NEWA

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL

	@	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Jan	DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETOPTIC

AT	+!	SANDOZ INC	EQ 0.5% BASE	N019270	001	Aug 30, 1985	Jan	CAHN

BICALUTAMIDE

TABLET;ORAL

CASODEX

AB	+!	ANI PHARMS INC	50MG	N020498	001	Oct 04, 1995	Jan	CAHN

>A> BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

>A> TABLET;ORAL

>A> BIKTARVY

>A>	+!	GILEAD SCIENCES INC	EQ 50MG BASE;200MG;EQ 25MG BASE	N210251	001	Feb 07, 2018	Feb	NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

	+!	ALLERGAN SALES LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jan	CAHN

BIVALIRUDIN

SOLUTION;IV (INFUSION)

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Jan	CAHN
	+!		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Jan	CAHN

BUMETANIDE

TABLET;ORAL

BUMETANIDE

AB		UPSHER-SMITH LABS	0.5MG	A209916	001	Jan 23, 2018	Jan	NEWA
AB			1MG	A209916	002	Jan 23, 2018	Jan	NEWA
AB			2MG	A209916	003	Jan 23, 2018	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB2		SCIEGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>A> AB		AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb	CAHN
>A> AB			10MG	A078246	002	Feb 27, 2009	Feb	CAHN
>A> AB			15MG	A078246	003	Feb 27, 2009	Feb	CAHN
>A> AB			30MG	A078246	004	Feb 27, 2009	Feb	CAHN
>D> AB		DR REDDYS LABS LTD	5MG	A078246	001	Feb 27, 2009	Feb	CAHN
>D> AB			10MG	A078246	002	Feb 27, 2009	Feb	CAHN
>D> AB			15MG	A078246	003	Feb 27, 2009	Feb	CAHN
>D> AB			30MG	A078246	004	Feb 27, 2009	Feb	CAHN
	@	FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan	CAHN
	@		10MG	A075413	002	Mar 19, 2002	Jan	CAHN
	@		15MG	A075413	003	Mar 19, 2002	Jan	CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988	Jan	CRLD
+	@		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988	Jan	CRLD

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988	Jan	CRLD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	002	Oct 17, 1988	Jan	CRLD
+	@		20MG/100ML;5GM/100ML;328MG/100ML;	N019685	008	Oct 17, 1988	Jan	DISC

			INJECTABLE;INJECTION						
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
				600MG/100ML;310MG/100ML					
			POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		+ @	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988	Jan	CRLD
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		+ @	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988	Jan	DISC
			POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		+ @	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988	Jan	CRLD
			CANDESARTAN CILEXETIL						
			TABLET;ORAL						
			ATACAND						
	AB	+	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN
	AB	+		8MG	N020838	002	Jun 04, 1998	Jan	CAHN
	AB	+		16MG	N020838	003	Jun 04, 1998	Jan	CAHN
	AB	+!		32MG	N020838	004	Jun 04, 1998	Jan	CAHN
			CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE						
			TABLET;ORAL						
			ATACAND HCT						
>A>	AB	+	ANI PHARMS INC	16MG;12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
>A>	AB	+		32MG;12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
>A>	AB	+!		32MG;25MG	N021093	003	May 16, 2008	Feb	CAHN
>D>	AB	+	ASTRAZENECA	16MG;12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
>D>	AB	+		32MG;12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
>D>	AB	+!		32MG;25MG	N021093	003	May 16, 2008	Feb	CAHN
			CAPTOPRIL						
			TABLET;ORAL						
			CAPTOPRIL						
		@	YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Jan	CAHN
		@		12.5MG	A074519	001	Feb 13, 1996	Jan	CAHN
		@		25MG	A074363	002	Nov 09, 1995	Jan	CAHN
		@		25MG	A074519	002	Feb 13, 1996	Jan	CAHN
		@		50MG	A074363	003	Nov 09, 1995	Jan	CAHN
		@		50MG	A074519	003	Feb 13, 1996	Jan	CAHN
		@		100MG	A074363	004	Nov 09, 1995	Jan	CAHN
		@		100MG	A074519	004	Feb 13, 1996	Jan	CAHN
			CAPTOPRIL; HYDROCHLOROTHIAZIDE						
			TABLET;ORAL						
			CAPTOPRIL AND HYDROCHLOROTHIAZIDE						
		@	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Jan	DISC
		@		25MG;25MG	A074827	002	Dec 29, 1997	Jan	DISC
		@		50MG;15MG	A074827	004	Dec 29, 1997	Jan	DISC
		@		50MG;25MG	A074827	003	Dec 29, 1997	Jan	DISC
			MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Jan	CTEC
		!		25MG;25MG	A074896	002	Dec 29, 1997	Jan	CTEC
		!		50MG;15MG	A074896	004	Dec 29, 1997	Jan	CTEC
				50MG;25MG	A074896	003	Dec 29, 1997	Jan	CTEC
			CARIPRAZINE HYDROCHLORIDE						
			CAPSULE;ORAL						
			VRAYLAR						
		+	ALLERGAN SALES LLC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CAHN
		+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CAHN
		+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan	CAHN
		+!		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CAHN
			CARISOPRODOL						
			TABLET;ORAL						
			CARISOPRODOL						
		@	FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

@	FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jan CAHN
@		EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jan CAHN
@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jan CAHN

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME SODIUM

>D> AP	LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003	Feb DISC
>A>	@	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003	Feb DISC
>D> AP		EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003	Feb DISC
>A>	@	EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003	Feb DISC
>D> AP		EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003	Feb DISC
>A>	@	EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003	Feb DISC

CEFTAROLINE FOSAMIL

POWDER;IV (INFUSION)

TEFLARO

+	ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010	Jan CAHN
+!		600MG/VIAL	N200327	002	Oct 29, 2010	Jan CAHN

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

@	SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jan CAHN

FOR SUSPENSION;ORAL

CEDAX

+ @	SI PHARMS	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jan CAHN
+ @		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jan CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

>D> AP	LUPIN	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006	Feb DISC
>A>	@	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006	Feb DISC

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

@	SANDOZ INC	EQ 250MG BASE	A065126	001	Oct 28, 2003	Jan CAHN
@		EQ 500MG BASE	A065126	002	Oct 28, 2003	Jan CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	CSPC OUYI PHARM CO	50MG	A210071	001	Jan 23, 2018	Jan NEWA
AB		100MG	A210071	002	Jan 23, 2018	Jan NEWA
AB		200MG	A210071	003	Jan 23, 2018	Jan NEWA

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

SONAZINE

@	FOSUN PHARMA	30MG/ML	A080983	004		Jan CAHN
@		100MG/ML	A080983	005		Jan CAHN

SYRUP;ORAL

SONAZINE

@	FOSUN PHARMA	10MG/5ML	A083040	001		Jan CAHN

CICLOPIROX

SOLUTION;TOPICAL

CICLOPIROX

AT	INGENUS PHARMS LLC	8%	A078124	001	Sep 18, 2007	Jan CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@	CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994	Jan	CMS1
@		300MG	A074329	003	May 17, 1994	Jan	CMS1
@		400MG	A074329	004	May 17, 1994	Jan	CMS1
@	YAOPHARMA CO LTD	200MG	A074100	001	Jan 31, 1995	Jan	CAHN
@		300MG	A074100	002	Jan 31, 1995	Jan	CAHN
@		400MG	A074100	003	Jan 31, 1995	Jan	CAHN
@		800MG	A074100	004	Jan 31, 1995	Jan	CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>A>								
>A>	AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A206125	001	Mar 08, 2018	Feb	NEWA
>A>	AB		EQ 60MG BASE	A206125	002	Mar 08, 2018	Feb	NEWA
>A>	AB		EQ 90MG BASE	A206125	003	Mar 08, 2018	Feb	NEWA
>A>	AB	CIPLA LTD	EQ 30MG BASE	A208915	001	Mar 08, 2018	Feb	NEWA
>A>	AB		EQ 60MG BASE	A208915	002	Mar 08, 2018	Feb	NEWA
>A>	AB		EQ 90MG BASE	A208915	003	Mar 08, 2018	Feb	NEWA

SENSIPAR

>D>	+	AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb	CFTG
>A>	AB +		EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb	CFTG
>D>	+		EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb	CFTG
>A>	AB +		EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb	CFTG
>D>	+!		EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb	CFTG
>A>	AB +!		EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb	CFTG

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	INFORLIFE	200MG/100ML	A078252	001	Mar 18, 2008	Jan	CAHN
AP		400MG/200ML	A078252	002	Mar 18, 2008	Jan	CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan	CAHN
@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan	CAHN
@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan	CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007	Jan	CAHN

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan	CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan	CAHN
AB	+!		EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan	CAHN
@			EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan	CAHN

CITALOPRAM HYDROBROMIDE

@	FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan	CAHN
@		EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan	CAHN
@		EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan	CAHN
@		EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan	CAHN
@		EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan	CAHN
@		EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan	CAHN

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan	NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan NEWA

IMPOYZ

	+!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	Jan CMS1
	@		0.3MG	A070886	003	Aug 31, 1988	Jan CMS1

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1		JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan NEWA

CLOZAPINE

TABLET;ORAL

CLOZAPINE

>D> AB		ZYDUS PHARMS USA INC	25MG	A209480	001	Dec 06, 2017	Feb DISC
>A>	@		25MG	A209480	001	Dec 06, 2017	Feb DISC
>D> AB			50MG	A209480	002	Dec 06, 2017	Feb DISC
>A>	@		50MG	A209480	002	Dec 06, 2017	Feb DISC
>D> AB			100MG	A209480	003	Dec 06, 2017	Feb DISC
>A>	@		100MG	A209480	003	Dec 06, 2017	Feb DISC
>D> AB			200MG	A209480	004	Dec 06, 2017	Feb DISC
>A>	@		200MG	A209480	004	Dec 06, 2017	Feb DISC

CROMOLYN SODIUM

SOLUTION/DROPS;OPHTHALMIC

CROMOLYN SODIUM

AT		SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan CAHN

CROTAMITON

CREAM;TOPICAL

EURAX

>D>	+!	RANBAXY	10%	N006927	001		Feb CAHN
>A>	+!	SUN PHARM INDS INC	10%	N006927	001		Feb CAHN

LOTION;TOPICAL

EURAX

>D> AT	+!	RANBAXY	10%	N009112	003		Feb CAHN
>A> AT	+!	SUN PHARM INDS INC	10%	N009112	003		Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOGYL

>A> AT	!	ALCON LABS INC	0.5%	A084109	001		Feb CAHN
>A> AT	!		1%	A084110	001		Feb CAHN
>A>	!		2%	A084108	001		Feb CAHN
>D> AT	!	NOVARTIS PHARMS CORP	0.5%	A084109	001		Feb CAHN
>D> AT	!		1%	A084110	001		Feb CAHN
>D>	!		2%	A084108	001		Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

>A>	!	ALCON LABS INC	0.2%;1%	A084300	001		Feb CAHN
>D>	!	NOVARTIS PHARMS CORP	0.2%;1%	A084300	001		Feb CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	FOSUN PHARMA	4MG	A086808	001		Jan CAHN
AA		MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan CAHN

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

	AP	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011		Jan CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

>D>	AP	TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016		Feb CAHN
>A>	AP	TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016		Feb CAHN

DESFLURANE

LIQUID;INHALATION

>A>		DESFLURANE						
>A>	AN	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018		Feb NEWA

SUPRANE

>D>		+! BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992		Feb CFTG
>A>	AN	+!	100%	N020118	001	Sep 18, 1992		Feb CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

>D>	AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016		Feb CAHN
>D>	AB		25MG	A205153	002	Oct 28, 2016		Feb CAHN
>D>	AB		50MG	A205153	003	Oct 28, 2016		Feb CAHN
>D>	AB		75MG	A205153	004	Oct 28, 2016		Feb CAHN
>D>	AB		100MG	A205153	005	Oct 28, 2016		Feb CAHN
>D>	AB		150MG	A205153	006	Oct 28, 2016		Feb CAHN
>A>	AB	MOUNTAIN	10MG	A205153	001	Oct 28, 2016		Feb CAHN
>A>	AB		25MG	A205153	002	Oct 28, 2016		Feb CAHN
>A>	AB		50MG	A205153	003	Oct 28, 2016		Feb CAHN
>A>	AB		75MG	A205153	004	Oct 28, 2016		Feb CAHN
>A>	AB		100MG	A205153	005	Oct 28, 2016		Feb CAHN
>A>	AB		150MG	A205153	006	Oct 28, 2016		Feb CAHN

DEXAMETHASONE

ELIXIR;ORAL

HEXADROL

>A>		@ ASPEN GLOBAL INC	0.5MG/5ML	N012674	001			Feb CAHN
>D>		@ ORGANON USA INC	0.5MG/5ML	N012674	001			Feb CAHN

SUSPENSION;INTRAOCULAR

DEXYCU KIT

>A>		+! ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018		Feb NEWA

TABLET;ORAL

DEXAMETHASONE

	BP	FERA PHARMS LLC	0.5MG	A088148	001	Apr 28, 1983		Jan CAHN
	BP		0.75MG	A088160	001	Apr 28, 1983		Jan CAHN
	BP		4MG	A088238	001	Apr 28, 1983		Jan CAHN
	BP		6MG	A088481	001	Nov 28, 1983		Jan CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

HEXADROL

>A>		+ @ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694	002			Feb CAHN
>A>		+ @	EQ 10MG PHOSPHATE/ML	N014694	003			Feb CAHN
>A>		@	EQ 20MG PHOSPHATE/ML	N014694	004			Feb CAHN
>D>		+ @ ORGANON USA INC	EQ 4MG PHOSPHATE/ML	N014694	002			Feb CAHN
>D>		+ @	EQ 10MG PHOSPHATE/ML	N014694	003			Feb CAHN
>D>		@	EQ 20MG PHOSPHATE/ML	N014694	004			Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP	ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018		Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH W/ DEXTROMETHORPHAN

		@	G AND W LABS INC	15MG/5ML;6.25MG/5ML	A088762	001	Oct 31, 1984	Jan DISC

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+!	HOSPIRA	50MG/ML	N019222	001	Jul 13, 1984	Feb	CAHN
>A>	AP	+!	ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984	Feb	CAHN

DEXTROSE 70% IN PLASTIC CONTAINER

>A>	AP	+!	B BRAUN	70GM/100ML	N019626	005	Feb 18, 2015	Feb	NEWA

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	AP	+	ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001		Jan	CRLD

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

	AB	+!	ALLERGAN SALES LLC	10MG	N007409	003	Oct 15, 1984	Jan	CAHN

INJECTABLE;INJECTION

BENTYL

	AP	+!	ALLERGAN SALES LLC	10MG/ML	N008370	001	Oct 15, 1984	Jan	CAHN

BENTYL PRESERVATIVE FREE

	AP	+!	ALLERGAN SALES LLC	10MG/ML	N008370	002	Oct 15, 1984	Jan	CAHN

TABLET;ORAL

BENTYL

	AB	+!	ALLERGAN SALES LLC	20MG	N007409	001	Oct 15, 1984	Jan	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

		@	FOSUN PHARMA	25MG	A080832	001		Jan	CAHN
		@		25MG	A080845	002		Jan	CAHN
		@		50MG	A080832	002		Jan	CAHN
		@		50MG	A080845	001		Jan	CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

	AP		AMNEAL PHARMS CO	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Jan	NEWA
	AP			80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Jan	NEWA
	AP			160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Jan	NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

		@	ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013	Jan	DISC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

	AB		HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Jan	NEWA
	AB			EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan	NEWA
	AB			EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan	NEWA
	AB			EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan	NEWA
	AB		IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan	CMFD
	AB			EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan	CMFD
	AB			EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan	CMFD
	AB			EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan	CMFD
		@	YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN
		@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan	CAHN
		@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan	CAHN
		@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan	CAHN

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan DISC
@		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan DISC

SILENOR

+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan CTEC
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

LO-ZUMANDIMINE

>A> AB	AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb NEWA

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

>A> AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb NEWA

>A> EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET;ORAL

>A> SYMFI LO

>A>	+! MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Feb NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

>A> AP	SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb NEWA
>A> AP		75MG/100ML	A204693	002	Mar 07, 2018	Feb NEWA

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

+	MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jan CMS1
+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jan CMS1

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

>A> AB	AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Feb NEWA
>A> AB		500MG	A209720	002	Mar 09, 2018	Feb NEWA
>D>	ARBOR PHARMS LLC	250MG	A061621	001		Feb CTEC
>A> AB		250MG	A061621	001		Feb CTEC
>D>	!	500MG	A061621	002		Feb CTEC
>A> AB	!	500MG	A061621	002		Feb CTEC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

LEXAPRO

AA	+! ALLERGAN SALES LLC	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN

TABLET;ORAL

LEXAPRO

AB	+ ALLERGAN SALES LLC	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
AB	+	EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
AB	+!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

>A> AB	ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb NEWA
AB	PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan NEWA

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

		@	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan CAHN
		@		20MG/ML	A040628	002	Oct 04, 2007	Jan CAHN
		@		40MG/ML	A040628	003	Oct 04, 2007	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

>A>	AB		ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

BALCOLTRA

>A>			AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Feb CAHN
>D>			NEUVOSYN LABS LLC	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Feb CAHN
				0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

MODICON 28

>D>	AB	+!	JANSSEN PHARMS	0.035MG;0.5MG	N017735	001		Feb DISC
>A>		+ @		0.035MG;0.5MG	N017735	001		Feb DISC

WERA

>D>	AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Feb CHRS
>A>	AB	!		0.035MG;0.5MG	A091204	001	Mar 27, 2012	Feb CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

		+ @	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>A>		@	PLD ACQUISITIONS	20MG	A075302	001	Apr 16, 2001	Feb CAHN
>A>		@		40MG	A075302	002	Apr 16, 2001	Feb CAHN
>D>		@	SANDOZ	20MG	A075302	001	Apr 16, 2001	Feb CAHN
>D>		@		40MG	A075302	002	Apr 16, 2001	Feb CAHN

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

	AB		AMNEAL PHARMS LLC	48MG	A209951	001	Feb 09, 2018	Jan NEWA
	AB			145MG	A209951	002	Feb 09, 2018	Jan NEWA

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

DURAGESIC-37

		+	JANSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018	Jan NEWA

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	AP	!	INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Jan CAHN
	AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Jan CAHN

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

		@	G AND W LABS	0.025%	A089525	001	Jul 26, 1988	Jan DISC

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

		@	G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Jan DISC

FLUORESCEIN SODIUM

INJECTABLE;INTRAVENOUS

FLUORESCITE

>A>	AP	+!	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb	CAHN
>D>	AP	+!	NOVARTIS PHARMS CORP	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb	CAHN

FLUOXETINE HYDROCHLORIDE

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

		@	FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002	Jan	CAHN

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

		@	YAOPHARMA CO LTD	125MG	A075818	001	Sep 18, 2001	Jan	CAHN

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

XHANCE

		+!	OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017	Jan	CMS1

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	AB		EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Jan	CAHN
	AB	!		20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CAHN

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

		@	YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Jan	CAHN

GENTAMICIN SULFATE

OINTMENT;TOPICAL

GENTAMICIN SULFATE

	AT		G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Jan	CMFD

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

GLATOPA

	AP		SANDOZ INC	40MG/ML	A206921	001	Feb 12, 2018	Jan	NEWA

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

		@	YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998	Jan	CAHN
		@		3MG	A075174	002	Jun 22, 1998	Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	!	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	Feb	DISC
>A>		@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	Feb	DISC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRISEOFULVIN, ULTRAMICROSIZE

	AB		MOUNTAIN	125MG	A204371	001	Jan 09, 2014	Jan	CAHN
	AB			250MG	A204371	002	Jan 09, 2014	Jan	CAHN

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

		@	YAOPHARMA CO LTD	EQ 4MG BASE	A074517	001	Sep 30, 1998	Jan	CAHN
		@		EQ 8MG BASE	A074517	002	Sep 30, 1998	Jan	CAHN

HALCINONIDE

CREAM;TOPICAL

HALOG

>D>		+!	RANBAXY	0.1%	N017556	001		Feb CAHN
>A>		+!	SUN PHARM INDS INC	0.1%	N017556	001		Feb CAHN

HALOBETASOL PROPIONATE

CREAM;TOPICAL

ULTRAVATE

>A>	AB	+	SUN PHARM INDS INC	0.05%	N019967	001	Dec 27, 1990	Feb CAHN
>D>	AB	+	SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Feb CAHN

OINTMENT;TOPICAL

ULTRAVATE

>D>	AB	+	RANBAXY	0.05%	N019968	001	Dec 17, 1990	Feb CAHN
>A>	AB	+	SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990	Feb CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

		@	FOSUN PHARMA	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Jan CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	AA		SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	Feb CAHN
>A>	AA			25MG	A205236	002	May 26, 2017	Feb CAHN
>A>	AA			50MG	A205236	003	May 26, 2017	Feb CAHN
>A>	AA			100MG	A205236	004	May 26, 2017	Feb CAHN
>D>	AA		TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Feb CAHN
>D>	AA			25MG	A205236	002	May 26, 2017	Feb CAHN
>D>	AA			50MG	A205236	003	May 26, 2017	Feb CAHN
>D>	AA			100MG	A205236	004	May 26, 2017	Feb CAHN

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	AB		SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jan CAHN
	AB			50MG	A203018	002	Jul 23, 2014	Jan CAHN
		@	YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982	Jan CAHN
		@		50MG	A084912	001		Jan CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		@	YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986	Jan CAHN
		@		25MG;250MG	A070183	001	Jan 15, 1986	Jan CAHN
		@		30MG;500MG	A070543	001	Jan 15, 1986	Jan CAHN
		@		50MG;500MG	A070544	001	Jan 15, 1986	Jan CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@	YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987	Jan CAHN
		@		25MG;80MG	A071061	001	Aug 26, 1987	Jan CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

		@	YAOPHARMA CO LTD	25MG;25MG	A086881	001		Jan CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

+	@	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan DISC
+	@		30MG	N207975	002	Jan 17, 2017	Jan DISC
+	@		45MG	N207975	003	Jan 17, 2017	Jan DISC
+	@		60MG	N207975	004	Jan 17, 2017	Jan DISC
+	@		90MG	N207975	005	Jan 17, 2017	Jan DISC

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL

WESTCORT

>D>		+ @	RANBAXY	0.2%	N018726	001	Aug 08, 1983	Feb CAHN
>A>		+ @	SUN PHARM INDS INC	0.2%	N018726	001	Aug 08, 1983	Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

	AB		ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018	Jan NEWA
	AB			4MG	A210506	002	Jan 17, 2018	Jan NEWA
	AB			8MG	A210506	003	Jan 17, 2018	Jan NEWA

HYDROXYPROGESTERONE CAPROATE

SOLUTION;SUBCUTANEOUS

MAKENA (AUTOINJECTOR)

>A>		+!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

ATARAX

>D>			@	PFIZER	10MG	N010392	001	Feb CRLD
>A>		+	@		10MG	N010392	001	Feb CRLD
>D>			@		25MG	N010392	004	Feb CRLD
>A>		+	@		25MG	N010392	004	Feb CRLD
>D>			@		50MG	N010392	006	Feb CRLD
>A>		+	@		50MG	N010392	006	Feb CRLD
>D>			@		100MG	N010392	005	Feb CRLD
>A>		+	@		100MG	N010392	005	Feb CRLD

IBRUTINIB

TABLET;ORAL

IMBRUVICA

>A>		+		PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb NEWA
>A>		+			280MG	N210563	002	Feb 16, 2018	Feb NEWA
>A>		+			420MG	N210563	003	Feb 16, 2018	Feb NEWA
>A>		+!			560MG	N210563	004	Feb 16, 2018	Feb NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

>A>				AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb NEWA

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

			@	MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010	Jan DISC

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

			@	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan DISC

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

			@	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan CAHN
			@		2.5MG	A074594	002	May 23, 1996	Jan CAHN

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

ATROVENT

		+	@	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995	Jan DISC
		+	@		0.042MG/SPRAY	N020394	001	Oct 20, 1995	Jan DISC

IPRATROPIUM BROMIDE

	AB	!		WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan CHRS
	AB	!			0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan CHRS

>A>		IVACAFTOR; IVACAFTOR, TEZACAFTOR						
>A>		TABLET, TABLET;ORAL						
>A>		SYMDEKO (COPACKAGED)						
>A>		+! VERTEX PHARMS INC	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Feb NEWA	
		KETOROLAC TROMETHAMINE						
		SOLUTION/DROPS;OPHTHALMIC						
		KETOROLAC TROMETHAMINE						
	AT	SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	Jan CAHN	
>A>		LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE						
>A>		TABLET;ORAL						
>A>		CIMDUO						
>A>		+! MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	Feb NEWA	
		LEFLUNOMIDE						
		TABLET;ORAL						
		LEFLUNOMIDE						
		@ FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan CAHN	
		@	20MG	A077087	002	Sep 13, 2005	Jan CAHN	
		LEUPROLIDE ACETATE						
		INJECTABLE;INJECTION						
		LUPRON						
>D>		@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Feb CRLD	
>A>		+ @	1MG/0.2ML	N019010	001	Apr 09, 1985	Feb CRLD	
		LEVETIRACETAM						
		TABLET;ORAL						
		LEVETIRACETAM						
		@ FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009	Jan CAHN	
		@	500MG	A077324	002	Jan 15, 2009	Jan CAHN	
		@	750MG	A077324	003	Jan 15, 2009	Jan CAHN	
		@	1GM	A077324	004	Jan 15, 2009	Jan CAHN	
		LEVOCETIRIZINE DIHYDROCHLORIDE						
		TABLET;ORAL						
		LEVOCETIRIZINE DIHYDROCHLORIDE						
		@ FOSUN PHARMA	5MG	A090486	001	Mar 26, 2013	Jan CAHN	
		LEVOFLOXACIN						
		INJECTABLE;INJECTION						
>D>		LEVAQUIN						
>D>	AP	+! JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb DISC	
>A>		+ @	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb DISC	
>D>	AP	+!	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb DISC	
>A>		+ @	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb DISC	
		LEVOFLOXACIN						
>D>	AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb DISC	
>A>		@	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb DISC	
>D>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb DISC	
>A>		@	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb DISC	
		LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP	! INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan CAHN	
	AP	!	EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan CAHN	
	AP	!	EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan CAHN	
		TABLET;ORAL						
>D>		LEVAQUIN						
>D>	AB	+ JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996	Feb DISC	
>A>		+ @	250MG	N020634	001	Dec 20, 1996	Feb DISC	
>D>	AB	+	500MG	N020634	002	Dec 20, 1996	Feb DISC	
>A>		+ @	500MG	N020634	002	Dec 20, 1996	Feb DISC	
>D>	AB	+!	750MG	N020634	003	Sep 08, 2000	Feb DISC	
>A>		+ @	750MG	N020634	003	Sep 08, 2000	Feb DISC	
		LEVOFLOXACIN						
>D>	AB	AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb CHRS	
>A>	AB	!	750MG	A201043	003	Jun 20, 2011	Feb CHRS	

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CAHN
+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CAHN
+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CAHN
+!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CAHN

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan	CAHN
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jan	CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan	NEWA

PATCH;TOPICAL

ZTLIDO

>A>	+! SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb	NEWA

LINACLOTIDE

CAPSULE;ORAL

LINZESS

+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan	CAHN
+		145MCG	N202811	001	Aug 30, 2012	Jan	CAHN
+!		290MCG	N202811	002	Aug 30, 2012	Jan	CAHN

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

@	YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992	Jan	CAHN

LORAZEPAM

TABLET;ORAL

LORAZEPAM

@	MYLAN	0.5MG	A071591	002	Oct 13, 1987	Jan	CMS1
@		1MG	A071591	003	Oct 13, 1987	Jan	CMS1

LUTETIUM DOTATATE LU-177

SOLUTION;IV (INFUSION)

LUTATHERA

+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jan	NEWA

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+!	STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan	CAHN

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

>D>	+! JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb	DISC
>A>	+ @	500MG	N208398	001	Oct 19, 2016	Feb	DISC

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

@	FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan	CAHN
@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan	CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

>A> AB	MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb	CAHN
>D> AB	VIVA HLTHCARE	250MG	A090562	001	Nov 19, 2010	Feb	CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan NEWA

NAMENDA

AA	+!	ALLERGAN SALES LLC	2MG/ML	N021627	001	Apr 18, 2005	Jan CAHN

TABLET;ORAL

NAMENDA

AB	+	ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003	Jan CAHN
AB	+!		10MG	N021487	002	Oct 16, 2003	Jan CAHN

MEROPENEM; VABORBACTAM

POWDER;IV (INFUSION)

VABOMERE

	+!	REMPEX PHARMS	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	Jan CAHN

MESALAMINE

ENEMA;RECTAL

MESALAMINE

	@	G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Jan DISC

SUPPOSITORY;RECTAL

CANASA

	@	ALLERGAN SALES LLC	500MG	N021252	001	Jan 05, 2001	Jan CAHN
AB	+!		1GM	N021252	002	Nov 05, 2004	Jan CAHN

MESNA

INJECTABLE;INTRAVENOUS

MESNA

	@	MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Jan DISC

>D> METARAMINOL BITARTRATE

>D> INJECTABLE;INJECTION

>D> METARAMINOL BITARTRATE

>D>	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001		Feb DISC
>A>	@		EQ 10MG BASE/ML	A080722	001		Feb DISC

METAXALONE

TABLET;ORAL

METAXALONE

		MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Jan CAHN
	@	PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Jan CAHN

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

>A> AA		ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	Feb CAHN
>A> AA			750MG	A203550	002	Feb 08, 2017	Feb CAHN
>D> AA		ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Feb CAHN
>D> AA			750MG	A203550	002	Feb 08, 2017	Feb CAHN
	@	FOSUN PHARMA	500MG	A084616	001		Jan CAHN
	@		750MG	A084615	001		Jan CAHN

METHYCLOTHIAZIDE

TABLET;ORAL

METHYCLOTHIAZIDE

	@	YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988	Jan CAHN
	@		5MG	A089837	001	Aug 18, 1988	Jan CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

	@	YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988	Jan CAHN
	@		250MG	N018934	001	Jun 29, 1984	Jan CAHN
	@		500MG	N018934	002	Jun 29, 1984	Jan CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB1	MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb	NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb	NEWA
>A>	AB		10MG	A209753	002	Mar 02, 2018	Feb	NEWA
>A>	AB		20MG	A209753	003	Mar 02, 2018	Feb	NEWA
	AB	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan	CAHN
	AB		10MG	A091159	002	Mar 12, 2014	Jan	CAHN
	AB		20MG	A091159	003	Mar 12, 2014	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	AB	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan	NEWA
	AB		27MG	A207515	002	Feb 01, 2018	Jan	NEWA
	AB		36MG	A207515	003	Feb 01, 2018	Jan	NEWA
	AB		54MG	A207515	004	Feb 01, 2018	Jan	NEWA
	AB	MOUNTAIN	18MG	A208607	001	Jul 14, 2017	Jan	CAHN
	AB		27MG	A208607	002	Jul 14, 2017	Jan	CAHN
	AB		36MG	A208607	003	Jul 14, 2017	Jan	CAHN
	AB		54MG	A208607	004	Jul 14, 2017	Jan	CAHN
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan	CHRS

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@	YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995	Jan	CAHN
	@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Jan	CAHN
	@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

	+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA
	+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA
	+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA
	+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

	AB	NOVAST LABS LTD	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA
	AB		EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA
	AB		EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan	NEWA
	AB		EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan	NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

	@	RENATA	50MG	A074453	001	Apr 27, 1995	Jan	CAHN
	@		100MG	A074453	002	Apr 27, 1995	Jan	CAHN
	@	YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan	CAHN
	@		100MG	A073289	001	Mar 25, 1994	Jan	CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

	@	FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan	CAHN
	@		250MG	N018740	001	Oct 22, 1982	Jan	CAHN
	@		500MG	N018620	002	Jun 02, 1983	Jan	CAHN
	@		500MG	N018740	002	Oct 22, 1982	Jan	CAHN

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

>D>	BX	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC
>A>	AB		2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC
>D>	BX		5MG	A077746	002	Sep 12, 2006	Feb	CTEC
>A>	AB		5MG	A077746	002	Sep 12, 2006	Feb	CTEC
>D>	BX		10MG	A077746	003	Sep 12, 2006	Feb	CTEC
>A>	AB		10MG	A077746	003	Sep 12, 2006	Feb	CTEC

MINOCYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

MINOCIN

	+!	REMPEX PHARMS	EQ 100MG BASE/VIAL	N050444	001			Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012		Jan CMFD
AB			EQ 115MG BASE	A065485	005	May 18, 2012		Jan CMFD

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

	@	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000		Jan CAHN

NAPROXEN

TABLET;ORAL

NAPROXEN

	@	FOSUN PHARMA	250MG	A074140	001	Dec 21, 1993		Jan CAHN
	@		375MG	A074140	002	Dec 21, 1993		Jan CAHN
	@		500MG	A074140	003	Dec 21, 1993		Jan CAHN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

	@	FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998		Jan CAHN
	@		500MG	A075061	002	Feb 18, 1998		Jan CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

>A>		AUROBINDO PHARMA LTD	500MG;EQ 85MG BASE	A207457	001	Feb 15, 2018		Feb NEWA

TREXIMET

>D>	+!	PERNIX IRELAND LTD	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008		Feb CFTG
>A>	AB +!		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008		Feb CFTG

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

>D>	+	ALLERGAN SALES LLC	EQ 2.5MG BASE	N021742	002	Dec 17, 2007		Feb CFTG
>A>	AB +		EQ 2.5MG BASE	N021742	002	Dec 17, 2007		Feb CFTG
	+		EQ 2.5MG BASE	N021742	002	Dec 17, 2007		Jan CAHN
>D>	+		EQ 5MG BASE	N021742	003	Dec 17, 2007		Feb CFTG
>A>	AB +		EQ 5MG BASE	N021742	003	Dec 17, 2007		Feb CFTG
	+		EQ 5MG BASE	N021742	003	Dec 17, 2007		Jan CAHN
>D>	+		EQ 10MG BASE	N021742	004	Dec 17, 2007		Feb CFTG
>A>	AB +		EQ 10MG BASE	N021742	004	Dec 17, 2007		Feb CFTG
	+		EQ 10MG BASE	N021742	004	Dec 17, 2007		Jan CAHN
>D>	+!		EQ 20MG BASE	N021742	005	Oct 08, 2008		Feb CFTG
>A>	AB +!		EQ 20MG BASE	N021742	005	Oct 08, 2008		Feb CFTG
	+!		EQ 20MG BASE	N021742	005	Oct 08, 2008		Jan CAHN

NEBIVOLOL HYDROCHLORIDE

>A>		TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018		Feb NEWA
>A>	AB		EQ 5MG BASE	A203966	002	Mar 02, 2018		Feb NEWA
>A>	AB		EQ 10MG BASE	A203966	003	Mar 02, 2018		Feb NEWA
>A>	AB		EQ 20MG BASE	A203966	004	Mar 02, 2018		Feb NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

	+!	ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016		Jan CAHN

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	@	FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003		Jan CAHN
	@		100MG	A076302	002	Sep 16, 2003		Jan CAHN
	@		150MG	A076302	003	Sep 16, 2003		Jan CAHN
	@		200MG	A076302	004	Sep 16, 2003		Jan CAHN
	@		250MG	A076302	005	Sep 16, 2003		Jan CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

>A>	AP	+!	AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb CAHN
>A>	AP	+!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb CAHN
>D>	AP	+!	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb CAHN
>D>	AP	+!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb CAHN

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

		@	TECH ORGANIZED	200MG	A203176	001	May 22, 2012	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

		@	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Jan DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

	AB		AUROBINDO PHARMA LTD	500MG	A209236	001	Feb 01, 2018	Jan NEWA
	AB			750MG	A209236	002	Feb 01, 2018	Jan NEWA
	AB			1GM	A209236	003	Feb 01, 2018	Jan NEWA

NITROGLYCERIN

OINTMENT;INTRA-ANAL

RECTIV

		+!	ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	Jan CAHN

TABLET;SUBLINGUAL

NITROGLYCERIN

	AB		GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan CAHN
	AB			0.4MG	A206391	002	Sep 19, 2017	Jan CAHN
	AB			0.6MG	A206391	003	Sep 19, 2017	Jan CAHN

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

		@	G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Jan DISC

SUSPENSION;ORAL

NYSTATIN

		@	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Jan DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A>	AT		AMNEAL PHARMS LLC	100,000 UNITS/GM;0.1%	A209990	001	Feb 15, 2018	Feb NEWA

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

	AT		STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Jan NEWA

ORITAVANCIN DIPHOSPHATE

POWDER;IV (INFUSION)

ORBACTIV

		+!	MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

>A>	AB		HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb NEWA
>A>	AB			EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb NEWA
>A>	AB			EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

>A>	AB		LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb NEWA

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

>A>	AP		ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb NEWA
>A>	AP			100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb NEWA

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

>D>			DITROPAN XL						
>D>	AB	+	JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Feb	DISC
>A>		+ @		5MG	N020897	001	Dec 16, 1998	Feb	DISC
>D>	AB	+		10MG	N020897	002	Dec 16, 1998	Feb	DISC
>A>		+ @		10MG	N020897	002	Dec 16, 1998	Feb	DISC
>D>	AB	+!		15MG	N020897	003	Jun 22, 1999	Feb	DISC
>A>		+ @		15MG	N020897	003	Jun 22, 1999	Feb	DISC
			OXYBUTYNIN CHLORIDE						
>D>	AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb	CHRS
>A>	AB	!		15MG	A076644	002	May 10, 2007	Feb	CHRS

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

			OXYMORPHONE HYDROCHLORIDE						
	AB		ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan	NEWA
	AB			10MG	A210175	002	Feb 02, 2018	Jan	NEWA

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

			TERRAMYCIN W/ POLYMYXIN B SULFATE						
>D>		!	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001		Feb	CMS2
>A>		!		EQ 5MG BASE/GM;10,000 UNITS/GM	N061015	001		Feb	CMS2

PEMOLINE

TABLET;ORAL

			PEMOLINE						
		@	FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan	CAHN
		@		37.5MG	A075286	002	Jun 30, 1999	Jan	CAHN
		@		75MG	A075286	003	Jun 30, 1999	Jan	CAHN

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

			PERMAPEN						
>D>	BC		CASPER PHARMA LLC	600,000 UNITS/ML	A060014	001		Feb	CMS2
>A>	BC			600,000 UNITS/ML	N060014	001		Feb	CMS2

PERINDOPRIL ERBUMINE

TABLET;ORAL

			PERINDOPRIL ERBUMINE						
		@	APOTEX	2MG	A090463	001	Aug 30, 2010	Jan	DISC
		@		4MG	A090463	002	Aug 30, 2010	Jan	DISC
		@		8MG	A090463	003	Aug 30, 2010	Jan	DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

			PHENTERMINE HYDROCHLORIDE						
		@	ELITE LABS INC	15MG	A040460	001	Jan 14, 2003	Jan	CAHN

PHENYLBUTAZONE

CAPSULE;ORAL

			PHENYLBUTAZONE						
		@	FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982	Jan	CAHN

TABLET;ORAL

			PHENYLBUTAZONE						
		@	FOSUN PHARMA	100MG	A084339	001		Jan	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

			PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE						
	AA	!	VINTAGE	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan	CHRS
			PROMETH VC PLAIN						
		@	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan	DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

	AB		WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

	AP		WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CPOT

PIROXICAM

CAPSULE;ORAL

PIROXICAM

>A>	AB		LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb NEWA
>A>	AB			20MG	A208991	002	Feb 21, 2018	Feb NEWA
>D>	AB	+	MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb CRLD
>A>	AB			10MG	A206152	001	Dec 29, 2017	Feb CRLD
>D>	AB	+		20MG	A206152	002	Dec 29, 2017	Feb CRLD
>A>	AB			20MG	A206152	002	Dec 29, 2017	Feb CRLD
	AB		STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan NEWA
	AB			20MG	A210347	002	Jan 26, 2018	Jan NEWA

POLIDOCANOL

SOLUTION;INTRAVENOUS

VARITHENA

		+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan CDFR

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

K-TAB

	AB3	+	ABBVIE	10MEQ	N018279	001		Jan CTEC
	AB2	+!		20MEQ	N018279	003	Nov 25, 2013	Jan CTEC

POTASSIUM CHLORIDE

	AB3		PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan NEWA
	AB2			20MEQ	A209688	002	Jan 12, 2018	Jan NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

	AB		MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan CAHN
	AB			10MEQ	A077440	002	Jun 09, 2006	Jan CAHN
>A>	AB		TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb NEWA
>A>	AB			10MEQ	A209758	002	Mar 05, 2018	Feb NEWA
>A>	AB			15MEQ	A209758	003	Mar 05, 2018	Feb NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

	AB		ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan NEWA
	AB			EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan NEWA
	AB		USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan CAHN
	AB			EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan CAHN

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

		@	FOSUN PHARMA	5MG	A080339	001		Jan CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

	AA	!	WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

>A>	AT	!	ALCON LABS INC	0.5%	A080027	001		Feb CAHN
>D>	AT	!	NOVARTIS PHARMS CORP	0.5%	A080027	001		Feb CAHN

PROPRANOLOL HYDROCHLORIDE

		INJECTABLE;INJECTION						
		PROPRANOLOL HYDROCHLORIDE						
		@ FOSUN PHARMA	1MG/ML	A	076400	001	Feb 26, 2003	Jan CAHN
		TABLET;ORAL						
		PROPRANOLOL HYDROCHLORIDE						
		@ YAOPHARMA CO LTD	10MG	A	070663	001	Jun 13, 1986	Jan CAHN
		@	20MG	A	070664	001	Jun 13, 1986	Jan CAHN
		@	40MG	A	070665	001	Jun 13, 1986	Jan CAHN
		@	60MG	A	070666	001	Oct 10, 1986	Jan CAHN
		@	80MG	A	070667	001	Jun 13, 1986	Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

		TABLET;ORAL						
		CORPHED						
		@ FOSUN PHARMA	60MG;2.5MG	A	088602	001	Apr 11, 1985	Jan CAHN

PYRIMETHAMINE

		TABLET;ORAL						
		DARAPRIM						
	+!	VYERA PHARMS LLC	25MG	N	008578	001		Jan CAHN

QUAZEPAM

		TABLET;ORAL						
		DORAL						
>D>	@	CUTIS HEALTH LLC	7.5MG	N	018708	003	Feb 26, 1987	Feb CAHN
>D>	+!		15MG	N	018708	001	Dec 27, 1985	Feb CAHN
>A>	@	GALT PHARMS	7.5MG	N	018708	003	Feb 26, 1987	Feb CAHN
>A>	+!		15MG	N	018708	001	Dec 27, 1985	Feb CAHN

QUINAPRIL HYDROCHLORIDE

		TABLET;ORAL						
		QUINAPRIL HYDROCHLORIDE						
	@	YAOPHARMA CO LTD	EQ 5MG BASE	A	076803	001	Mar 02, 2005	Jan CAHN
	@		EQ 10MG BASE	A	076803	002	Mar 02, 2005	Jan CAHN
	@		EQ 20MG BASE	A	076803	003	Mar 02, 2005	Jan CAHN
	@		EQ 40MG BASE	A	076803	004	Mar 02, 2005	Jan CAHN

QUINIDINE SULFATE

		TABLET, EXTENDED RELEASE;ORAL						
		QUINIDINE SULFATE						
	@	G AND W LABS INC	300MG	A	040045	001	Jun 30, 1994	Jan DISC

RABEPRAZOLE SODIUM

		CAPSULE, DELAYED RELEASE;ORAL						
		ACIPHEX SPRINKLE						
>D>	+	AVADEL PHARMS	5MG	N	204736	001	Mar 26, 2013	Feb CAHN
>D>	+!		10MG	N	204736	002	Mar 26, 2013	Feb CAHN
>A>	+	CERECOR INC	5MG	N	204736	001	Mar 26, 2013	Feb CAHN
>A>	+!		10MG	N	204736	002	Mar 26, 2013	Feb CAHN

RAMIPRIL

		CAPSULE;ORAL						
		RAMIPRIL						
	@	YAOPHARMA CO LTD	1.25MG	A	077514	001	Jun 18, 2008	Jan CAHN
	@		2.5MG	A	077514	002	Jun 18, 2008	Jan CAHN
	@		5MG	A	077514	003	Jun 18, 2008	Jan CAHN
	@		10MG	A	077514	004	Jun 18, 2008	Jan CAHN

REMIFENTANIL HYDROCHLORIDE

		INJECTABLE;INJECTION						
		REMIFENTANIL HYDROCHLORIDE						
AP		FRESENIUS KABI USA	EQ 1MG BASE/VIAL	A	206223	001	Jan 16, 2018	Jan NEWA
AP			EQ 2MG BASE/VIAL	A	206223	002	Jan 16, 2018	Jan NEWA
AP			EQ 5MG BASE/VIAL	A	206223	003	Jan 16, 2018	Jan NEWA
		ULTIVA						
AP	+	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N	020630	001	Jul 12, 1996	Jan CFTG
AP	+		EQ 2MG BASE/VIAL	N	020630	002	Jul 12, 1996	Jan CFTG
AP	+!		EQ 5MG BASE/VIAL	N	020630	003	Jul 12, 1996	Jan CFTG

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB		RENATA	0.25MG	A078707	001	Dec 29, 2008	Jan CAHN
AB			0.5MG	A078707	002	Dec 29, 2008	Jan CAHN
AB			1MG	A078707	003	Dec 29, 2008	Jan CAHN
AB			2MG	A078707	004	Dec 29, 2008	Jan CAHN
AB			3MG	A078707	005	Dec 29, 2008	Jan CAHN
AB			4MG	A078707	006	Dec 29, 2008	Jan CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

	+	ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018	Jan NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

	@	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Jan DISC
	@		EQ 0.5MG BASE	A077460	002	May 05, 2008	Jan DISC
	@		EQ 1MG BASE	A077460	003	May 05, 2008	Jan DISC
	@		EQ 2MG BASE	A077460	004	May 05, 2008	Jan DISC
	@		EQ 3MG BASE	A077460	005	May 05, 2008	Jan DISC
	@		EQ 4MG BASE	A077460	006	May 05, 2008	Jan DISC
	@		EQ 5MG BASE	A077460	007	May 19, 2008	Jan DISC

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan CAHN
	@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan CAHN
	@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan CAHN

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

	@	YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan CAHN
	@		10MG	A077766	002	Dec 20, 2006	Jan CAHN
	@		20MG	A077766	003	Dec 20, 2006	Jan CAHN
	@		40MG	A077766	004	Dec 20, 2006	Jan CAHN
	@		80MG	A077766	005	Dec 20, 2006	Jan CAHN

SINECATECHINS

OINTMENT;TOPICAL

VEREGEN

	+!	FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006	Jan CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	+! HOSPIRA	9MG/ML	N019217	001	Jul 13, 1984	Feb CAHN
>A>	AP	+! ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Feb CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

>A>	AP	SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN
>D>	AP	ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

>A> SOMATROPIN

>A> INJECTABLE;INJECTION

>A> BIO-TROPIN

>A>		@ FERRING	4.8MG/VIAL	N019774	001	May 25, 1995	Feb CAIN

>A> ZOMACTON

>A>	BX	+! FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb CAIN
>A>		+	10MG/VIAL	N019774	003	Mar 07, 2012	Feb CAIN

>D>		SOMATROPIN RECOMBINANT						
>D>		INJECTABLE;INJECTION						
>D>		BIO-TROPIN						
>D>		@ FERRING	4.8MG/VIAL	N019774	001	May 25, 1995	Feb	CAIN
>D>		ZOMACTON						
>D>	BX	+! FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb	CAIN
>D>		+	10MG/VIAL	N019774	003	Mar 07, 2012	Feb	CAIN
		SUCRALFATE						
		SUSPENSION;ORAL						
		CARAFATE						
		+! ALLERGAN SALES LLC	1GM/10ML	N019183	001	Dec 16, 1993	Jan	CAHN
		TABLET;ORAL						
		CARAFATE						
	AB	+! ALLERGAN SALES LLC	1GM	N018333	001		Jan	CAHN
		SULFAMETHOXAZOLE; TRIMETHOPRIM						
		TABLET;ORAL						
		SULFAMETHOXAZOLE AND TRIMETHOPRIM						
		@ FOSUN PHARMA	400MG;80MG	A070889	001	Nov 13, 1986	Jan	CAHN
		@	400MG;80MG	N018598	003	May 19, 1982	Jan	CAHN
		@	800MG;160MG	A070890	001	Nov 13, 1986	Jan	CAHN
		SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
		@ FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982	Jan	CAHN
		SULINDAC						
		TABLET;ORAL						
		SULINDAC						
		@ FOSUN PHARMA	150MG	A072712	001	Aug 30, 1991	Jan	CAHN
		@	200MG	A072713	001	Aug 30, 1991	Jan	CAHN
		SUMATRIPTAN SUCCINATE						
		TABLET;ORAL						
		SUMATRIPTAN SUCCINATE						
		@ FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009	Jan	CAHN
		@	EQ 50MG BASE	A076976	002	Aug 10, 2009	Jan	CAHN
		@	EQ 100MG BASE	A076976	003	Aug 10, 2009	Jan	CAHN
		TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT						
		INJECTABLE;INJECTION						
>D>		PULMOLITE						
>D>	BS	+! JUBILANT DRAXIMAGE	N/A	N017776	001		Feb	DISC
>A>		+ @	N/A	N017776	001		Feb	DISC
		TECHNETIUM TC-99M MEDRONATE KIT						
		INJECTABLE;INJECTION						
		CIS-MDP						
		PHARMALUCENCE	N/A	N018124	001		Jan	CTEC
		MDP-BRACCO						
		@ CARDINAL HEALTH 414	N/A	N018107	001		Jan	DISC
		TECHNETIUM TC-99M PENTETATE KIT						
		INJECTABLE;INJECTION						
		DTPA						
		+! JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan	CAHN
		TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR						
>A>		SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC						
>A>		RADIOGENIX SYSTEM						
>A>		+ NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Feb	NEWA
		TENOFOVIR DISOPROXIL FUMARATE						
		TABLET;ORAL						
		TENOFOVIR DISOPROXIL FUMARATE						
	AB	AUROBINDO PHARMA LTD	150MG	A090647	001	Jan 26, 2018	Jan	NEWA
	AB		200MG	A090647	002	Jan 26, 2018	Jan	NEWA
	AB		250MG	A090647	003	Jan 26, 2018	Jan	NEWA
	AB		300MG	A090647	004	Jan 26, 2018	Jan	NEWA
	AB	CIPLA LTD	300MG	A078800	001	Jan 26, 2018	Jan	NEWA
	AB	HETERO LABS LTD III	300MG	A090636	001	Jan 26, 2018	Jan	NEWA
>A>	AB	LAURUS LABS PVT	300MG	A209550	001	Feb 26, 2018	Feb	NEWA

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

	AB		MACLEODS PHARMS LTD	300MG	A203232	001	Jan 26, 2018	Jan NEWA
>A>	AB		QILU TIANHE	200MG	A209498	001	Mar 02, 2018	Feb NEWA
>A>	AB			250MG	A209498	002	Mar 02, 2018	Feb NEWA
>A>	AB			300MG	A209498	003	Mar 02, 2018	Feb NEWA
	AB		STRIDES PHARMA	300MG	A090742	001	Jan 26, 2018	Jan NEWA
	AB		TEVA PHARMS USA	150MG	A091612	002	Jan 26, 2018	Jan NEWA
	AB			200MG	A091612	003	Jan 26, 2018	Jan NEWA
	AB			250MG	A091612	004	Jan 26, 2018	Jan NEWA

VIREAD

	AB	+	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Jan CFTG
	AB	+		200MG	N021356	003	Jan 18, 2012	Jan CFTG
	AB	+		250MG	N021356	004	Jan 18, 2012	Jan CFTG

TERCONAZOLE

CREAM;VAGINAL

>D>			TERAZOL 7					
>D>	AB	+!	JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987	Feb DISC
>A>		+ @		0.4%	N019579	001	Dec 31, 1987	Feb DISC
			TERCONAZOLE					
>D>	AB		TARO	0.4%	A076043	001	Jan 19, 2005	Feb CHRS
>A>	AB	!		0.4%	A076043	001	Jan 19, 2005	Feb CHRS

SUPPOSITORY;VAGINAL

>D>			TERAZOL 3					
>D>	AB	+!	JANSSEN PHARMS	80MG	N019641	001	May 24, 1988	Feb DISC
>A>		+ @		80MG	N019641	001	May 24, 1988	Feb DISC
			TERCONAZOLE					
>D>	AB		PERRIGO NEW YORK	80MG	A077149	001	Mar 17, 2006	Feb CHRS
>A>	AB	!		80MG	A077149	001	Mar 17, 2006	Feb CHRS

TESTOSTERONE

GEL;TRANSDERMAL
TESTOSTERONE

			@ ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jan DISC
			@	50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jan DISC

SOLUTION, METERED;TRANSDERMAL
TESTOSTERONE

	AT		CIPLA LTD	30MG/1.5ML ACTUATION	A209533	001	Jan 29, 2018	Jan NEWA

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

	AB		NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Jan CTEC
	AB			200MG	A087400	004	Feb 21, 1985	Jan CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

			@ FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan CAHN
			@	25MG	A088133	001	Aug 30, 1983	Jan CAHN
			@	50MG	A088134	001	Aug 30, 1983	Jan CAHN
			@	100MG	A088135	001	Nov 20, 1984	Jan CAHN
			@	200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTHIXENE

CAPSULE;ORAL
NAVANE

		+ @	PFIZER	1MG	N016584	001		Jan CRLD
		+ @		2MG	N016584	002		Jan CRLD
		+ @		5MG	N016584	003		Jan CRLD
		+ @		10MG	N016584	004		Jan CRLD
		+ @		20MG	N016584	005		Jan CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

			@ YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan CAHN
			@	250MG	A075326	001	Aug 20, 1999	Jan CAHN

TIGECYCLINE
POWDER;IV (INFUSION)
TIGECYCLINE

			ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jan NEWA

TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT	+		ATON	EQ 0.25% BASE	N018086	001		Jan CMFD
AT1	+			EQ 0.5% BASE	N018086	002		Jan CMFD

TABLET;ORAL
TIMOLOL MALEATE

		@	YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan CAHN
		@		10MG	A072551	001	Apr 13, 1989	Jan CAHN
		@		20MG	A072552	001	Apr 13, 1989	Jan CAHN

TIZANIDINE HYDROCHLORIDE
TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

>A>	AB		ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb NEWA
>A>	AB			EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb NEWA

TOLAZAMIDE
TABLET;ORAL
TOLAZAMIDE

		@	YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987	Jan CAHN
		@		250MG	A070289	001	Mar 13, 1986	Jan CAHN
		@		500MG	A070290	001	Mar 13, 1986	Jan CAHN

TOLBUTAMIDE
TABLET;ORAL
TOLBUTAMIDE

		@	YAOPHARMA CO LTD	500MG	A086574	001		Jan CAHN

TOLMETIN SODIUM
CAPSULE;ORAL
TOLMETIN SODIUM

		@	FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992	Jan CAHN

TABLET;ORAL
TOLMETIN SODIUM

		@	FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992	Jan CAHN
		@		EQ 600MG BASE	A074002	001	Sep 27, 1993	Jan CAHN

TOPIRAMATE
CAPSULE;ORAL
TOPIRAMATE

		@	FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009	Jan CAHN
		@		25MG	A079206	002	Oct 14, 2009	Jan CAHN

TRAMADOL HYDROCHLORIDE
TABLET;ORAL
TRAMADOL HYDROCHLORIDE

		@	FOSUN PHARMA	50MG	A075968	001	Jun 25, 2002	Jan CAHN

TRAZODONE HYDROCHLORIDE
TABLET;ORAL
TRAZODONE HYDROCHLORIDE

		@	FOSUN PHARMA	100MG	A072483	001	Apr 30, 1990	Jan CAHN

TRIAMCINOLONE ACETONIDE
SPRAY;TOPICAL
KENALOG

>D>	AT	+!	RANBAXY LABS LTD	0.147MG/GM	N012104	001		Feb CAHN
>A>	AT	+!	SUN PHARM INDS INC	0.147MG/GM	N012104	001		Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

SYPRINE

AB	+!	ATON	250MG	N019194	001	Nov 08, 1985	Jan	CFTG

TRIENTINE HYDROCHLORIDE

AB		WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018	Jan	NEWA

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

	@	FOSUN PHARMA	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

>D> AB		FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012	Feb	DISC
>A>	@		EQ 125MG BASE	A065453	001	Jun 18, 2012	Feb	DISC
>D> AB			EQ 250MG BASE	A065453	002	Jun 18, 2012	Feb	DISC
>A>	@		EQ 250MG BASE	A065453	002	Jun 18, 2012	Feb	DISC

FOR SOLUTION;ORAL

FIRVANQ KIT

	+!	RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jan	NEWA
	+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jan	NEWA

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

>A>	+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Feb	CAHN
>A>	+!		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CAHN
>D>	+	PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006	Feb	CAHN
>D>	+!		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

	@	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan	CAHN
	@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan	CAHN
	@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan	CAHN
	@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan	CAHN
	@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987	Jan	CPOT

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

	@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan	CAHN
	@		80MG	A071423	001	May 24, 1988	Jan	CAHN
	@		120MG	A071424	001	May 25, 1988	Jan	CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

>A> AA		AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb	NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan	CAHN
	+		20MG	N022567	002	Jan 21, 2011	Jan	CAHN
	+		40MG	N022567	003	Jan 21, 2011	Jan	CAHN

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

	@	YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan	CAHN
	@		2MG	A040196	002	Sep 30, 1997	Jan	CAHN
	@		2.5MG	A040196	003	Sep 30, 1997	Jan	CAHN
	@		3MG	A040196	008	Jul 26, 2000	Jan	CAHN
	@		4MG	A040196	004	Sep 30, 1997	Jan	CAHN

TABLET;ORAL
WARFARIN SODIUM

		@	5MG		A040196	005	Sep 30, 1997	Jan CAHN
		@	6MG		A040196	009	Jul 26, 2000	Jan CAHN
		@	7.5MG		A040196	006	Sep 30, 1997	Jan CAHN
		@	10MG		A040196	007	Sep 30, 1997	Jan CAHN

ZOLEDRONIC ACID
INJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

	AP		INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan CAHN
	AP			EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan CAHN
>D>	AP	!	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb DISC
>A>		@		EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb DISC

ZONISAMIDE
CAPSULE;ORAL
ZONISAMIDE

>A>		@	AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb CAHN
>A>		@		50MG	A077645	003	Sep 29, 2006	Feb CAHN
>A>		@		100MG	A077645	001	Dec 22, 2005	Feb CAHN
>D>		@	DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Feb CAHN
>D>		@		50MG	A077645	003	Sep 29, 2006	Feb CAHN
>D>		@		100MG	A077645	001	Dec 22, 2005	Feb CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

	@ G AND W LABS	325MG	N018060	003	Dec 18, 1986		Jan DISC
	@	650MG	N018060	002			Jan DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007	Feb	CAHN
>A>		10MG	A077946	002	Dec 27, 2007	Feb	CAHN
>D>	SANDOZ	5MG	A077946	001	Dec 27, 2007	Feb	CAHN
>D>		10MG	A077946	002	Dec 27, 2007	Feb	CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008	Feb	CAHN
>D>	SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008	Feb	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

>A>	+! BECTON DICKINSON CO	2%;70% (1ML)	N020832	008	Oct 23, 2008	Feb	NEWA

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

	PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993	Jan	CAHN

CLOTRIMAZOLE

>D> CREAM, TABLET;TOPICAL, VAGINAL

>D> MYCELEX-7 COMBINATION PACK

>D>	BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994	Feb	DISC
>A>	@	1%,100MG	N020389	002	Jun 23, 1994	Feb	DISC

IBUPROFEN

TABLET;ORAL

IBUPROFEN

	@ P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986	Jan	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018	Jan	NEWA

LORATADINE

TABLET;ORAL

LORATADINE

	PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003	Jan	CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

	@ G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004	Jan	DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

	@ PLD ACQUISITIONS LLC	EQ 200MG BASE	A074646	001	Jan 13, 1997	Jan	CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

THRIVE

>A>	GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658	001	Jun 19, 2007	Feb	CAHN
>A>		EQ 4MG BASE	A077656	001	Jun 19, 2007	Feb	CAHN
>D>	NOVARTIS	EQ 2MG BASE	A077658	001	Jun 19, 2007	Feb	CAHN
>D>		EQ 4MG BASE	A077656	001	Jun 19, 2007	Feb	CAHN

TROCHE/LOZENGE;ORAL

>D>		COMMIT						
>D>	+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002	Feb	CTNA
>D>	+!		EQ 4MG BASE	N021330	002	Oct 31, 2002	Feb	CTNA
>A>		NICORETTE						
>A>	+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002	Feb	CTNA
>A>	+!		EQ 4MG BASE	N021330	002	Oct 31, 2002	Feb	CTNA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>A>		VIVIMED GLOBAL	EQ 75MG BASE	A209160	001	Mar 05, 2018	Feb	NEWA
>A>			EQ 150MG BASE	A209161	001	Feb 22, 2018	Feb	NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

>A>	+!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006	Feb	CAHN
>D>	+!	NOVARTIS	1%	N021958	001	Jul 24, 2006	Feb	CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

>A>	+!	GLAXOSMITHKLINE CONS	1%	N021124	001	Mar 17, 2000	Feb	CAHN
>D>	+!	NOVARTIS	1%	N021124	001	Mar 17, 2000	Feb	CAHN

SPRAY;TOPICAL

LAMISIL AT

>A>	+!	GLAXOSMITHKLINE CONS	1%	N021124	002	Mar 17, 2000	Feb	CAHN
>D>	+!	NOVARTIS	1%	N021124	002	Mar 17, 2000	Feb	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2018

NO FEBRUARY 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO FEBRUARY 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABEMACICLIB - VERZENIO							
N 208716	001					>A> I-768	Feb 26, 2021
ABEMACICLIB - VERZENIO							
N 208716	002					>A> I-768	Feb 26, 2021
ABEMACICLIB - VERZENIO							
N 208716	003					>A> I-768	Feb 26, 2021
ABEMACICLIB - VERZENIO							
N 208716	004					>A> I-768	Feb 26, 2021
ABIRATERONE ACETATE - ZYTIGA							
N 202379	001	>A> 8822438	Aug 24, 2027	U-1579		>A> I-765	Feb 07, 2021
		>A> 8822438	Aug 24, 2027	U-1580			
		>A> 8822438	Aug 24, 2027	U-2235			
ABIRATERONE ACETATE - ZYTIGA							
N 202379	002	>A> 8822438	Aug 24, 2027	U-1579		>A> I-765	Feb 07, 2021
		>A> 8822438	Aug 24, 2027	U-1580			
		>A> 8822438	Aug 24, 2027	U-2235			
AFATINIB DIMALEATE - GILOTRIF							
N 201292	001					I-763	Jan 12, 2021
AFATINIB DIMALEATE - GILOTRIF							
N 201292	002					I-763	Jan 12, 2021
AFATINIB DIMALEATE - GILOTRIF							
N 201292	003					I-763	Jan 12, 2021
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	002	9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	001	>A> 8252331	Mar 13, 2030	DP			
		>A> 8574626	Nov 28, 2025	DP U-20			
		>A> RE39069	May 29, 2018	DP			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	002	>A> 8252331	Mar 13, 2030	DP			
		>A> 8574626	Nov 28, 2025	DP U-20			
		>A> RE39069	May 29, 2018	DP			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	003	>A> 8252331	Mar 13, 2030	DP			
		>A> 8574626	Nov 28, 2025	DP U-20			
		>A> RE39069	May 29, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANGIOTENSIN II ACETATE - GIAPREZA							
N 209360 001		9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
		9220745	Dec 18, 2034	U-2218			
		9572856	Sep 20, 2030	U-2221			
	>A>	9867863	Dec 16, 2029	U-2231			
ANGIOTENSIN II ACETATE - GIAPREZA							
N 209360 002		9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
		9220745	Dec 18, 2034	U-2218			
		9572856	Sep 20, 2030	U-2221			
	>A>	9867863	Dec 16, 2029	U-2231			
APALUTAMIDE - ERLEADA							
N 210951 001	>A>	8445507	Sep 15, 2030	DS DP U-2237		>A> NCE	Feb 14, 2023
	>A>	8802689	Mar 27, 2027	U-2237			
	>A>	9388159	Mar 27, 2027	DS DP			
	>A>	9481663	Jun 04, 2033	DS DP U-2237			
	>A>	9884054	Sep 23, 2033	U-2237			
APREMILAST - OTEZLA							
N 205437 001	>A>	9872854	May 29, 2034	U-2232			
	>A>	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA							
N 205437 002	>A>	9872854	May 29, 2034	U-2232			
	>A>	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA							
N 205437 003	>A>	9872854	May 29, 2034	U-2232			
	>A>	9872854	May 29, 2034	U-2233			
ARSENIC TRIOXIDE - TRISENOX							
N 021248 001	>A>	6723351	Nov 10, 2018	U-2204			
	>A>	6723351	Nov 10, 2018	U-2229			
	>A>	6723351	Nov 10, 2018	U-573			
	>A>	6855339	Nov 10, 2018	U-2204			
	>A>	6855339	Nov 10, 2018	U-2229			
	>A>	6855339	Nov 10, 2018	U-617			
	>A>	6861076	Nov 10, 2018	U-2204			
	>A>	6861076	Nov 10, 2018	U-2229			
	>A>	6861076	Nov 10, 2018	U-617			
	>A>	6884439	Nov 10, 2018	U-2204			
	>A>	6884439	Nov 10, 2018	U-2229			
	>A>	6884439	Nov 10, 2018	U-651			
	>A>	6982096	Nov 10, 2018	U-2204			
	>A>	6982096	Nov 10, 2018	U-2229			
	>A>	6982096	Nov 10, 2018	U-651			
		8273379	Nov 10, 2018	U-1291			
		8273379	Nov 10, 2018	U-2204			
		8273379	Nov 10, 2018	U-2229			
ARSENIC TRIOXIDE - TRISENOX							
N 021248 002	>A>	6723351	Nov 10, 2018	U-2204			
	>A>	6723351	Nov 10, 2018	U-2229			
	>A>	6723351	Nov 10, 2018	U-573			
	>A>	6855339	Nov 10, 2018	U-2204			
	>A>	6855339	Nov 10, 2018	U-2229			
	>A>	6855339	Nov 10, 2018	U-617			
	>A>	6861076	Nov 10, 2018	U-2204			
	>A>	6861076	Nov 10, 2018	U-2229			
	>A>	6861076	Nov 10, 2018	U-617			
	>A>	6884439	Nov 10, 2018	U-2204			
	>A>	6884439	Nov 10, 2018	U-2229			
	>A>	6884439	Nov 10, 2018	U-651			
	>A>	6982096	Nov 10, 2018	U-2204			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARSENIC TRIOXIDE - TRISENOX							
N 021248	002	>A> 6982096	Nov 10, 2018	U-2229			
		>A> 6982096	Nov 10, 2018	U-651			
		>A> 8273379	Nov 10, 2018	U-2204			
		>A> 8273379	Nov 10, 2018	U-2229			
ASENAPINE MALEATE - SAPHRIS							
N 022117	001					M-158	Mar 12, 2018
						NPP	Mar 12, 2018
						PED	Sep 12, 2018
						PED	Sep 12, 2018
ASENAPINE MALEATE - SAPHRIS							
N 022117	002					M-158	Mar 12, 2018
						NPP	Mar 12, 2018
						PED	Sep 12, 2018
						PED	Sep 12, 2018
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	>A> 7112592	Feb 24, 2022	DS DP U-2244			
		>A> 7112592	Feb 24, 2022	DS DP U-282			
		>A> 8178554	Jul 24, 2021	DS DP U-2245			
		>A> 8178554	Jul 24, 2021	DS DP U-282			
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE							
N 022247	001	>A> 5998402	Apr 04, 2019	DS DP U-594			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA							
N 208194	001	8791270	Jan 12, 2026	DP U-1790			
BETAMETHASONE DIPROPIONATE - SERNIVO							
N 208079	001	>A> 9877974	Aug 31, 2030	DP U-1858			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY							
N 210251	001	>A> 6642245	Nov 04, 2020	U-257		>A> NCE	Feb 07, 2023
		>A> 6703396	Mar 09, 2021	DS DP			
		>A> 7390791	May 07, 2022	DS DP			
		>A> 7803788	Feb 02, 2022	U-257			
		>A> 8754065	Aug 15, 2032	DS DP U-257			
		>A> 9216996	Dec 19, 2033	DS DP			
		>A> 9296769	Aug 15, 2032	DS DP U-257			
		>A> 9708342	Jun 19, 2035	DS DP			
		>A> 9732092	Dec 19, 2033	DS DP			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	001					>A> ODE-163	Dec 19, 2024
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	002					>A> ODE-163	Dec 19, 2024
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	003					>A> ODE-163	Dec 19, 2024
BRIMONIDINE TARTRATE - MIRVASO							
N 204708	001	9861631	Mar 25, 2031	U-1428			
		9861632	Mar 25, 2031	U-1428			
BRIMONIDINE TARTRATE - LUMIFY							
N 208144	001	8293742	Jul 14, 2030	U-2222			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
N 021398	001	>A> 9907801	Apr 19, 2022	DP U-2239			
		>A> 9907802	Apr 19, 2022	DP U-2240			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	001	>A> 8387615	Mar 26, 2027	DP			
		>A> 8387615*PED	Sep 26, 2027				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	002	>A> 8387615	Mar 26, 2027	DP			
		>A> 8387615*PED	Sep 26, 2027				
BUPRENORPHINE - SUBLOCADE							
N 209819	001					NP	Nov 30, 2020
BUPRENORPHINE - SUBLOCADE							
N 209819	002					NP	Nov 30, 2020
CALCIFEDIOL - RAYALDEE							
N 208010	001	9861644	Mar 14, 2034	DP			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	001	>A> 7094427	May 29, 2022	DP U-1645	Y		
		>A> 9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	002	>A> 7094427	May 29, 2022	DP U-1645	Y		
		>A> 9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	003	>A> 7094427	May 29, 2022	DP U-1645	Y		
		>A> 9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	004	>A> 7094427	May 29, 2022	DP U-1645	Y		
		>A> 9901640	Dec 26, 2028	DP U-219			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	9872906	Mar 14, 2034	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB							
N 021524	001					>A> M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK							
N 021524	002					>A> M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK							
N 021524	003					>A> M-221	Feb 14, 2021
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX							
N 205395	001	>A> 9889115	Jun 23, 2019	U-1660			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	>A> 9891239	Sep 03, 2029	DP U-257			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD							
N 203100	001	>A> 9891239	Sep 03, 2029	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COCAINE HYDROCHLORIDE - GOPRELTO						
N 209963 001	9867815	Feb 07, 2037	U-2225		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001					ODE-162	Dec 22, 2024
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002					ODE-162	Dec 22, 2024
DANTROLENE SODIUM - RYANODEX						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
DASATINIB - SPRYCEL						
N 021986 001					>A> ODE-164	Nov 09, 2024
DASATINIB - SPRYCEL						
N 021986 002					>A> ODE-164	Nov 09, 2024
DASATINIB - SPRYCEL						
N 021986 003					>A> ODE-164	Nov 09, 2024
DASATINIB - SPRYCEL						
N 021986 004					>A> ODE-164	Nov 09, 2024
DASATINIB - SPRYCEL						
N 021986 005					>A> ODE-164	Nov 09, 2024
DASATINIB - SPRYCEL						
N 021986 006					>A> ODE-164	Nov 09, 2024
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 001					>A> M-222	Feb 06, 2021
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 002					>A> M-222	Feb 06, 2021
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003					>A> M-222	Feb 06, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXAMETHASONE - DEXYCU KIT							
N 208912	001	>A> 6960346	Jul 03, 2023	DP		>A> NP	Feb 09, 2021
		>A> 7560120	Sep 05, 2022	DP			
DIMETHYL FUMARATE - TECFIDERA							
N 204063	001	>A> 6509376	Apr 01, 2018	DP			
		>A> 7320999	Oct 20, 2018	U-1384			
		>A> 7619001	Apr 01, 2018	U-1384			
		>A> 7803840	Apr 01, 2018	U-1385			
		>A> 8399514	Feb 07, 2028	U-1384			
DIMETHYL FUMARATE - TECFIDERA							
N 204063	002	>A> 6509376	Apr 01, 2018	DP			
		>A> 7320999	Oct 20, 2018	U-1384			
		>A> 7619001	Apr 01, 2018	U-1384			
		>A> 7803840	Apr 01, 2018	U-1385			
		>A> 8399514	Feb 07, 2028	U-1384			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	001	9861607	May 18, 2027	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	002	9861607	May 18, 2027	U-620			
EFAVIRENZ - EFAVIRENZ							
A 078064	001					>A> PC	Jun 19, 2018
EFAVIRENZ - EFAVIRENZ							
A 078064	002					>A> PC	Jun 19, 2018
EFAVIRENZ - EFAVIRENZ							
A 078064	003					>A> PC	Jun 19, 2018
EFAVIRENZ - EFAVIRENZ							
A 091471	001					PC	Feb 14, 2018
EFINACONAZOLE - JUBLIA							
N 203567	001	9877955	Jan 03, 2028	U-1969			
ERTUGLIFLOZIN - STEGLATRO							
N 209803	001	8080580	Jul 13, 2030	DS DP U-2214			
ERTUGLIFLOZIN - STEGLATRO							
N 209803	002	8080580	Jul 13, 2030	DS DP U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	001	8080580	Jul 13, 2030	DS DP U-2214			
		9308204	Oct 21, 2030	DP			
		9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	002	8080580	Jul 13, 2030	DS DP U-2214			
		9308204	Oct 21, 2030	DP			
		9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	003	8080580	Jul 13, 2030	DS DP U-2214			
		9308204	Oct 21, 2030	DP			
		9439902	Oct 21, 2030	U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806	004	8080580	Jul 13, 2030	DS DP U-2214			
		9308204	Oct 21, 2030	DP			
		9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN							
N 209805	001	6699871	Jul 26, 2022	DS DP U-2214			
		6890898	Feb 02, 2019	U-2215			
		7078381	Feb 02, 2019	U-2216			
		7326708	Nov 24, 2026	DS DP U-2214			
		7459428	Feb 02, 2019	U-2215			
		8080580	Jul 13, 2030	DS DP U-2214			
		9308204	Oct 21, 2030	DP			
		9439901	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN							
N 209805	002	6699871	Jul 26, 2022	DS DP U-2214			
		6890898	Feb 02, 2019	U-2215			
		7078381	Feb 02, 2019	U-2216			
		7326708	Nov 24, 2026	DS DP U-2214			
		7459428	Feb 02, 2019	U-2215			
		8080580	Jul 13, 2030	DS DP U-2214			
		9308204	Oct 21, 2030	DP			
		9439901	Oct 21, 2030	U-2214			
EXENATIDE - BYDUREON BCISE							
N 209210	001	>A> 9884092	Aug 18, 2026	U-1313			
		>A> 9884092	Aug 18, 2026	U-2154			
		>A> 9884092	Aug 18, 2026	U-2155			
		>A> 9884092	Aug 18, 2026	U-2156			
EXENATIDE SYNTHETIC - BYDUREON							
N 022200	001	>A> 9884092	Aug 18, 2026	U-1313			
		>A> 9884092	Aug 18, 2026	U-2154			
		>A> 9884092	Aug 18, 2026	U-2155			
		>A> 9884092	Aug 18, 2026	U-2156			
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200	002	>A> 9884092	Aug 18, 2026	U-1313			
		>A> 9884092	Aug 18, 2026	U-2154			
		>A> 9884092	Aug 18, 2026	U-2155			
		>A> 9884092	Aug 18, 2026	U-2156			
FENTANYL CITRATE - LAZANDA							
N 022569	001	9814705	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA							
N 022569	002	9814705	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA							
N 022569	003	9814705	Jan 08, 2024	DP			
FERUMOXYTOL - FERAHEME							
N 022180	001					>A> I-767	Feb 02, 2021
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	001	9750726	Nov 29, 2030	DP			
FORMOTEROL FUMARATE - PERFOROMIST							
N 022007	001	9730890	Jun 22, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT							
N 022555	001					>A> M-220	Feb 15, 2021
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	001	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	002	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	003	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	004	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	005	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	006	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	007	9872837	Dec 21, 2031	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP							
N 019034	001	>A> 9248229	Mar 12, 2034	DP			
		>A> 9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP							
N 019034	002	>A> 9248229	Mar 12, 2034	DP			
		>A> 9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID							
N 019034	003	>A> 9248229	Mar 12, 2034	DP			
		>A> 9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID							
N 019034	004	>A> 9248229	Mar 12, 2034	DP			
		>A> 9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID							
N 019034	005	>A> 9248229	Mar 12, 2034	DP			
		>A> 9731082	Apr 23, 2032	DP			
HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)							
N 021945	004	>A> 8021335	Oct 04, 2026	DP			
		>A> 8562564	Jan 24, 2026	DP			
		>A> 9180259	Jan 24, 2026	DP			
		>A> 9533102	Jan 24, 2026	DP			
		>A> 9629959	Jan 24, 2026	DP			
		>A> 9789257	Feb 11, 2034	DP			
		>A> 9844558	May 02, 2036			U-2236	
		>A> RE44846	Aug 10, 2019	DP			
IBRUTINIB - IMBRUVICA							
N 205552	001	8563563	Apr 26, 2027			U-1491	
		8563563	Apr 26, 2027			U-1946	
		8563563	Apr 26, 2027			U-2219	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 205552	002	7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
		8008309	Dec 28, 2026	DS DP			
		8476284	Dec 28, 2026	U-1456			
		8476284	Dec 28, 2026	U-1650			
		8476284	Dec 28, 2026	U-1946			
		8476284	Dec 28, 2026	U-1947			
		8497277	Dec 28, 2026	U-1456			
		8497277	Dec 28, 2026	U-1491			
		8497277	Dec 28, 2026	U-1650			
		8497277	Dec 28, 2026	U-1946			
		8497277	Dec 28, 2026	U-1947			
		8563563	Apr 26, 2027	U-1491			
		8563563	Apr 26, 2027	U-1946			
		8563563	Apr 26, 2027	U-2219			
		8697711	Dec 28, 2026	DS DP			
		8703780	Dec 28, 2026	U-1491			
		8735403	Dec 28, 2026	DS DP			
		8754090	Jun 03, 2031	U-1456			
		8754091	Dec 28, 2026	DP			
		8952015	Dec 28, 2026	U-1456			
		8952015	Dec 28, 2026	U-1491			
		8952015	Dec 28, 2026	U-1650			
		8952015	Dec 28, 2026	U-1946			
		8952015	Dec 28, 2026	U-1947			
		8957079	Dec 28, 2026	DS DP			
		8999999	Jun 03, 2031	U-1491			
		8999999	Jun 03, 2031	U-1946			
		8999999	Jun 03, 2031	U-2228			
		9125889	Jun 03, 2031	U-1650			
		9181257	Dec 28, 2026	DS			
		9296753	Oct 30, 2033	DS			
		9540382	Aug 18, 2033	U-1456			
		9540382	Aug 18, 2033	U-1491			
		9540382	Aug 18, 2033	U-1650			
		9540382	Aug 18, 2033	U-1946			
		9540382	Aug 18, 2033	U-1947			
		9713617	Jun 03, 2033	DP			
		9725455	Jun 03, 2033	DS			
		9795604	Oct 24, 2034	U-2150			
		9801881	Jun 03, 2031	U-1491			
		9801883	Jun 03, 2031	U-2159			
		9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA							
N 210563	001	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
		>A> 8008309	Dec 28, 2026	DS DP			
		>A> 8476284	Dec 28, 2026	U-1456			
		>A> 8476284	Dec 28, 2026	U-1650			
		>A> 8476284	Dec 28, 2026	U-1946			
		>A> 8476284	Dec 28, 2026	U-1947			
		>A> 8476284	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-1456			
		>A> 8497277	Dec 28, 2026	U-1491			
		>A> 8497277	Dec 28, 2026	U-1650			
		>A> 8497277	Dec 28, 2026	U-1946			
		>A> 8497277	Dec 28, 2026	U-1947			
		>A> 8497277	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-2242			
		>A> 8563563	Apr 26, 2027	U-1491			
		>A> 8563563	Apr 26, 2027	U-1946			
		>A> 8563563	Apr 26, 2027	U-2241			
		>A> 8563563	Apr 26, 2027	U-2242			
		>A> 8697711	Dec 28, 2026	DS DP			
		>A> 8703780	Dec 28, 2026	U-1491			
		>A> 8703780	Dec 28, 2026	U-2242			
		>A> 8735403	Dec 28, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	001	>A> 8754090	Jun 03, 2031	U-1456			
		>A> 8754091	Dec 28, 2026	DP			
		>A> 8952015	Dec 28, 2026	U-1456			
		>A> 8952015	Dec 28, 2026	U-1491			
		>A> 8952015	Dec 28, 2026	U-1650			
		>A> 8952015	Dec 28, 2026	U-1946			
		>A> 8952015	Dec 28, 2026	U-1947			
		>A> 8952015	Dec 28, 2026	U-2241			
		>A> 8952015	Dec 28, 2026	U-2242			
		>A> 8957079	Dec 28, 2026	DS DP			
		>A> 8999999	Jun 03, 2031	U-1491			
		>A> 8999999	Jun 03, 2031	U-1946			
		>A> 8999999	Jun 03, 2031	U-2241			
		>A> 8999999	Jun 03, 2031	U-2242			
		>A> 9125889	Jun 03, 2031	U-1650			
		>A> 9181257	Dec 28, 2026	DS			
		>A> 9296753	Oct 30, 2033	DS			
		>A> 9655857	Mar 03, 2036	DP			
		>A> 9725455	Jun 03, 2033	DS			
		>A> 9795604	Oct 24, 2034	U-2150			
		>A> 9801881	Jun 03, 2031	U-1491			
		>A> 9801881	Jun 03, 2031	U-2242			
		>A> 9801883	Jun 03, 2031	U-2159			
		>A> 9801883	Jun 03, 2031	U-2243			
		>A> 9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA							
N 210563	002	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
		>A> 8008309	Dec 28, 2026	DS DP			
		>A> 8476284	Dec 28, 2026	U-1456			
		>A> 8476284	Dec 28, 2026	U-1650			
		>A> 8476284	Dec 28, 2026	U-1946			
		>A> 8476284	Dec 28, 2026	U-1947			
		>A> 8476284	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-1456			
		>A> 8497277	Dec 28, 2026	U-1491			
		>A> 8497277	Dec 28, 2026	U-1650			
		>A> 8497277	Dec 28, 2026	U-1946			
		>A> 8497277	Dec 28, 2026	U-1947			
		>A> 8497277	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-2242			
		>A> 8563563	Apr 26, 2027	U-1491			
		>A> 8563563	Apr 26, 2027	U-1946			
		>A> 8563563	Apr 26, 2027	U-2241			
		>A> 8563563	Apr 26, 2027	U-2242			
		>A> 8697711	Dec 28, 2026	DS DP			
		>A> 8703780	Dec 28, 2026	U-1491			
		>A> 8703780	Dec 28, 2026	U-2242			
		>A> 8735403	Dec 28, 2026	DS DP			
		>A> 8754090	Jun 03, 2031	U-1456			
		>A> 8754091	Dec 28, 2026	DP			
		>A> 8952015	Dec 28, 2026	U-1456			
		>A> 8952015	Dec 28, 2026	U-1491			
		>A> 8952015	Dec 28, 2026	U-1650			
		>A> 8952015	Dec 28, 2026	U-1946			
		>A> 8952015	Dec 28, 2026	U-1947			
		>A> 8952015	Dec 28, 2026	U-2241			
		>A> 8952015	Dec 28, 2026	U-2242			
		>A> 8957079	Dec 28, 2026	DS DP			
		>A> 8999999	Jun 03, 2031	U-1491			
		>A> 8999999	Jun 03, 2031	U-1946			
		>A> 8999999	Jun 03, 2031	U-2241			
		>A> 8999999	Jun 03, 2031	U-2242			
		>A> 9125889	Jun 03, 2031	U-1650			
		>A> 9181257	Dec 28, 2026	DS			
		>A> 9296753	Oct 30, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	002	>A> 9655857	Mar 03, 2036	DP			
		>A> 9725455	Jun 03, 2033	DS			
		>A> 9795604	Oct 24, 2034	U-2150			
		>A> 9801881	Jun 03, 2031	U-1491			
		>A> 9801881	Jun 03, 2031	U-2242			
		>A> 9801883	Jun 03, 2031	U-2159			
		>A> 9801883	Jun 03, 2031	U-2243			
		>A> 9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA							
N 210563	003	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
		>A> 8008309	Dec 28, 2026	DS DP			
		>A> 8476284	Dec 28, 2026	U-1456			
		>A> 8476284	Dec 28, 2026	U-1650			
		>A> 8476284	Dec 28, 2026	U-1946			
		>A> 8476284	Dec 28, 2026	U-1947			
		>A> 8476284	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-1456			
		>A> 8497277	Dec 28, 2026	U-1491			
		>A> 8497277	Dec 28, 2026	U-1650			
		>A> 8497277	Dec 28, 2026	U-1946			
		>A> 8497277	Dec 28, 2026	U-1947			
		>A> 8497277	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-2242			
		>A> 8563563	Apr 26, 2027	U-1491			
		>A> 8563563	Apr 26, 2027	U-1946			
		>A> 8563563	Apr 26, 2027	U-2241			
		>A> 8563563	Apr 26, 2027	U-2242			
		>A> 8697711	Dec 28, 2026	DS DP			
		>A> 8703780	Dec 28, 2026	U-1491			
		>A> 8703780	Dec 28, 2026	U-2242			
		>A> 8735403	Dec 28, 2026	DS DP			
		>A> 8754090	Jun 03, 2031	U-1456			
		>A> 8754091	Dec 28, 2026	DP			
		>A> 8952015	Dec 28, 2026	U-1456			
		>A> 8952015	Dec 28, 2026	U-1491			
		>A> 8952015	Dec 28, 2026	U-1650			
		>A> 8952015	Dec 28, 2026	U-1946			
		>A> 8952015	Dec 28, 2026	U-1947			
		>A> 8952015	Dec 28, 2026	U-2241			
		>A> 8952015	Dec 28, 2026	U-2242			
		>A> 8957079	Dec 28, 2026	DS DP			
		>A> 8999999	Jun 03, 2031	U-1491			
		>A> 8999999	Jun 03, 2031	U-1946			
		>A> 8999999	Jun 03, 2031	U-2241			
		>A> 8999999	Jun 03, 2031	U-2242			
		>A> 9125889	Jun 03, 2031	U-1650			
		>A> 9181257	Dec 28, 2026	DS			
		>A> 9296753	Oct 30, 2033	DS			
		>A> 9655857	Mar 03, 2036	DP			
		>A> 9725455	Jun 03, 2033	DS			
		>A> 9795604	Oct 24, 2034	U-2150			
		>A> 9801881	Jun 03, 2031	U-1491			
		>A> 9801881	Jun 03, 2031	U-2242			
		>A> 9801883	Jun 03, 2031	U-2159			
		>A> 9801883	Jun 03, 2031	U-2243			
		>A> 9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA							
N 210563	004	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
		>A> 8008309	Dec 28, 2026	DS DP			
		>A> 8476284	Dec 28, 2026	U-1456			
		>A> 8476284	Dec 28, 2026	U-1650			
		>A> 8476284	Dec 28, 2026	U-1946			
		>A> 8476284	Dec 28, 2026	U-1947			
		>A> 8476284	Dec 28, 2026	U-2241			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	004	>A> 8497277	Dec 28, 2026	U-1456			
		>A> 8497277	Dec 28, 2026	U-1491			
		>A> 8497277	Dec 28, 2026	U-1650			
		>A> 8497277	Dec 28, 2026	U-1946			
		>A> 8497277	Dec 28, 2026	U-1947			
		>A> 8497277	Dec 28, 2026	U-2241			
		>A> 8497277	Dec 28, 2026	U-2242			
		>A> 8563563	Apr 26, 2027	U-1491			
		>A> 8563563	Apr 26, 2027	U-1946			
		>A> 8563563	Apr 26, 2027	U-2241			
		>A> 8563563	Apr 26, 2027	U-2242			
		>A> 8697711	Dec 28, 2026	DS DP			
		>A> 8703780	Dec 28, 2026	U-1491			
		>A> 8703780	Dec 28, 2026	U-2242			
		>A> 8735403	Dec 28, 2026	DS DP			
		>A> 8754090	Jun 03, 2031	U-1456			
		>A> 8754091	Dec 28, 2026	DP			
		>A> 8952015	Dec 28, 2026	U-1456			
		>A> 8952015	Dec 28, 2026	U-1491			
		>A> 8952015	Dec 28, 2026	U-1650			
		>A> 8952015	Dec 28, 2026	U-1946			
		>A> 8952015	Dec 28, 2026	U-1947			
		>A> 8952015	Dec 28, 2026	U-2241			
		>A> 8952015	Dec 28, 2026	U-2242			
		>A> 8957079	Dec 28, 2026	DS DP			
		>A> 8999999	Jun 03, 2031	U-1491			
		>A> 8999999	Jun 03, 2031	U-1946			
		>A> 8999999	Jun 03, 2031	U-2241			
		>A> 8999999	Jun 03, 2031	U-2242			
		>A> 9125889	Jun 03, 2031	U-1650			
		>A> 9181257	Dec 28, 2026	DS			
		>A> 9296753	Oct 30, 2033	DS			
		>A> 9655857	Mar 03, 2036	DP			
		>A> 9725455	Jun 03, 2033	DS			
		>A> 9795604	Oct 24, 2034	U-2150			
		>A> 9801881	Jun 03, 2031	U-1491			
		>A> 9801881	Jun 03, 2031	U-2242			
		>A> 9801883	Jun 03, 2031	U-2159			
		>A> 9801883	Jun 03, 2031	U-2243			
		>A> 9814721	Jun 03, 2031	U-1947			
INGENOL MEBUTATE - PICATO							
N 202833	001	9861603	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO							
N 202833	002	9861603	Dec 18, 2026	U-1440			
INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30							
N 203313	001	>A> 9884094	May 01, 2033	U-2238			
IVACAFTOR - KALYDECO							
N 203188	001	>A> 8629162	Jun 24, 2025	U-2234			
IVACAFTOR - KALYDECO							
N 207925	001	>A> 8629162	Jun 24, 2025	U-2234			
IVACAFTOR - KALYDECO							
N 207925	002	>A> 8629162	Jun 24, 2025	U-2234			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	>A> 7495103	May 20, 2027	DS DP		>A> NCE	Feb 12, 2023
		>A> 7645789	May 01, 2027	DS DP			
		>A> 7776905	Jun 03, 2027	DS DP			
		>A> 8324242	Aug 05, 2027	U-2246			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	>A> 8410274	Dec 28, 2026	DP			
		>A> 8415387	Nov 12, 2027	U-2246			
		>A> 8598181	May 01, 2027	U-2246			
		>A> 8623905	May 01, 2027	DS DP			
		>A> 8629162	Jun 24, 2025	U-2247			
		>A> 8754224	Dec 28, 2026	DS DP			
		>A> 9012496	Jul 15, 2033	U-2248			
		>A> 9670163	Dec 28, 2026	DP U-2246			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001					M-218	Jan 25, 2021
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002					M-218	Jan 25, 2021
LETERMOVIR - PREVYMIS							
N 209939	001					>A> ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209939	002					>A> ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209940	001					>A> ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209940	002					>A> ODE-165	Nov 08, 2024
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	002	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	003	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	004	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	005	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	006	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	007	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	008	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	009	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	010	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT							
N 021924	013	7691411	Mar 14, 2024	DP			
		7723390	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIDOCAINE - ZTLIDO							
N 207962 001	>A>	9283174	May 10, 2031	DP		>A> NP	Feb 28, 2021
LIFITEGRAST - XIIDRA							
N 208073 001	>A>	9890141	Oct 21, 2030	DS			
LIXISENATIDE - ADLYXIN							
N 208471 001		9440029	Jan 30, 2032	DP			
		9855388	Apr 24, 2029	DP U-1881			
LIXISENATIDE - ADLYXIN							
N 208471 002		9440029	Jan 30, 2032	DP			
		9855388	Apr 24, 2029	DP U-1881			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 001		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 002		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 003		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 004		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 005		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 006		9861622	Mar 07, 2025	U-1316			
LULICONAZOLE - LUZU							
N 204153 001						>A> NPP	Feb 20, 2021
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 001		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 002		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 003		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 004		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 005		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
LUTETIUM DOTATATE LU-177 - LUTATHERA							
N 208700 001						NCE	Jan 26, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MACIMORELIN ACETATE - MACRILEN								
N 205598	001		6861409	Aug 01, 2022	DS DP U-2220			
			8192719	Oct 12, 2027	U-2220			
METFORMIN HYDROCHLORIDE - GLUMETZA								
N 021748	002	>A>	8323692	Mar 30, 2023	DP			
METHOTREXATE SODIUM - XATMEP								
N 208400	001		9855215	Jan 02, 2033	DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ								
N 205777	001	>A>	9907793	Apr 04, 2023	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ								
N 205777	002	>A>	9907793	Apr 04, 2023	DP U-1556			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA								
N 022068	001						D-170	Dec 22, 2020
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA								
N 022068	002						D-170	Dec 22, 2020
OLAPARIB - LYNPARZA								
N 208558	001						I-762	Jan 12, 2021
OLAPARIB - LYNPARZA								
N 208558	002						I-762	Jan 12, 2021
OSPEMIFENE - OSPHENA								
N 203505	001		9855224	Feb 13, 2024	U-1369			
			9855224	Feb 13, 2024	U-1370			
OZENOXACIN - XEPI								
N 208945	001		6335447	Apr 06, 2019	DS			
			9180200	Jan 29, 2032	DP U-805			
			9399014	Dec 15, 2029	U-805			
PIRFENIDONE - ESBRIET								
N 208780	001	>A>	8420674	Dec 18, 2027	U-2079			
PIRFENIDONE - ESBRIET								
N 208780	003	>A>	8420674	Dec 18, 2027	U-2079			
PLECANATIDE - TRULANCE								
N 208745	001	>A>	9610321	Sep 15, 2031	U-1999		I-764	Jan 24, 2021
		>A>	9610321	Sep 15, 2031	U-2230			
RIVAROXABAN - XARELTO								
N 022406	001		9415053	Nov 13, 2024	DP U-1167			
			9415053	Nov 13, 2024	DP U-1200			
			9415053	Nov 13, 2024	DP U-1301			
			9415053	Nov 13, 2024	DP U-1302			
			9415053	Nov 13, 2024	DP U-2142			
			9539218	Feb 17, 2034	U-1953			
			9539218	Feb 17, 2034	U-1954			
			9539218	Feb 17, 2034	U-1955			
			9539218	Feb 17, 2034	U-1957			
			9539218	Feb 17, 2034	U-2143			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO							
N 022406	002	7157456	Aug 28, 2024	DS DP U-1301			
		7157456	Aug 28, 2024	DS DP U-1302			
RIVAROXABAN - XARELTO							
N 022406	003	7157456	Aug 28, 2024	DS DP U-1301			
		7157456	Aug 28, 2024	DS DP U-1302			
		9415053	Nov 13, 2024	DP U-1167			
		9415053	Nov 13, 2024	DP U-1200			
		9415053	Nov 13, 2024	DP U-1301			
		9415053	Nov 13, 2024	DP U-1302			
ROFLUMILAST - DALIRESP							
N 022522	001					NS	Jan 23, 2021
ROFLUMILAST - DALIRESP							
N 022522	002					NS	Jan 23, 2021
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	006	>A> 7828787	Oct 18, 2025	DP			
		>A> 7857802	Nov 28, 2026	DP			
		>A> 8118802	May 18, 2023	DP			
		>A> 8162915	May 23, 2024	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	007	>A> 7828787	Oct 18, 2025	DP			
		>A> 7857802	Nov 28, 2026	DP			
		>A> 8118802	May 18, 2023	DP			
		>A> 8162915	May 23, 2024	DP			
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	001	9861638	Feb 10, 2031	U-2012			
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	002	9861638	Feb 10, 2031	U-2012			
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	003	9861638	Feb 10, 2031	U-2012			
SIMEPREVIR SODIUM - OLYSIO							
N 205123	001	9856265	Jul 28, 2026	DS DP U-1467			
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI							
N 209195	001	9868745	Nov 16, 2032	DS DP			
TADALAFIL - CIALIS							
N 021368	001					>A> M-219	Feb 15, 2021
						>A> PED	Aug 15, 2021
TADALAFIL - CIALIS							
N 021368	002					>A> M-219	Feb 15, 2021
						>A> PED	Aug 15, 2021
TADALAFIL - CIALIS							
N 021368	003					>A> M-219	Feb 15, 2021
						>A> PED	Aug 15, 2021
TADALAFIL - CIALIS							
N 021368	004					>A> M-219	Feb 15, 2021
						>A> PED	Aug 15, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ						
N 205677 001	9855241	Jan 25, 2033	U-2149			
VANDETANIB - CAPRELSA						
N 022405 001	>A> 7173038	Aug 14, 2021	DS DP			
	>A> 8642608	Feb 06, 2022	U-1490			
VANDETANIB - CAPRELSA						
N 022405 002	>A> 7173038	Aug 14, 2021	DS DP			
	>A> 8642608	Feb 06, 2022	U-1490			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 001	9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 003	9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm